,Assay,Weighted Partial Correlation
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,0.1727171096690775
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,-0.0
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,0.09167419713445021
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,-0.0
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,-0.0
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,0.17510385690693836
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,0.35683860024493147
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,0.35999143972641
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,0.4205142325442707
A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,-0.0
A High-Content qHTS Against Drug Library for the Identification of Small Molecules that Inhibit DYT1 Early Onset Primary Dystonia-Associated Cell Pathology,A High-Content qHTS Against Drug Library for the Identification of Small Molecules that Inhibit DYT1 Early Onset Primary Dystonia-Associated Cell Pathology,0.24416328257645498
A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,0.20729983483461908
A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,0.08488548526836795
A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,0.18580974803881717
A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,0.9029262506221485
A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,0.11401124806150369
A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,0.2248524763628353
Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,0.3292802349115067
Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),0.23563495182137212
Acetylcholinesterase (AChE) small molecule antagonists: colormetric cell-based qHTS assay,Acetylcholinesterase (AChE) small molecule antagonists: colormetric cell-based qHTS assay,-0.0
Acetylcholinesterase (AChE) small molecule antagonists: enzyme-based qHTS assay,Acetylcholinesterase (AChE) small molecule antagonists: enzyme-based qHTS assay,0.04557256131798285
Acetylcholinesterase (AChE) small molecule antagonists: fluorescence cell-based qHTS assay,Acetylcholinesterase (AChE) small molecule antagonists: fluorescence cell-based qHTS assay,0.13824429135574356
Agonist activity at human ADRA1A in an in vitro cell-based assay (CRO assay) measured by fluorescence spectroscopy,Agonist activity at human ADRA1A in an in vitro cell-based assay (CRO assay) measured by fluorescence spectroscopy,0.0
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,-0.0
Antagonist activity at human ADRA1A in an in vitro cell-based assay measured by fluorescence spectroscopy,Antagonist activity at human ADRA1A in an in vitro cell-based assay measured by fluorescence spectroscopy,0.0
Antagonist activity at human TBXA2R in an in vitro cell-based assay measured by fluorescence spectroscopy,Antagonist activity at human TBXA2R in an in vitro cell-based assay measured by fluorescence spectroscopy,0.0
Antagonist activity human CHRM1 in an in vitro cell-based assay measured by fluorescence spectroscopy,Antagonist activity human CHRM1 in an in vitro cell-based assay measured by fluorescence spectroscopy,0.0
Antagonist of Human D 1 Dopamine Receptor: qHTS,Antagonist of Human D 1 Dopamine Receptor: qHTS,0.050193192564467574
Binding affinity towards human ADORA3 (agonistic activity) in an in vitro assay with cellular components measured by scintillation counting,Binding affinity towards human ADORA3 (agonistic activity) in an in vitro assay with cellular components measured by scintillation counting,0.0
Binding affinity towards human ADRA2A in an in vitro assay with cellular components measured by scintillation counting,Binding affinity towards human ADRA2A in an in vitro assay with cellular components measured by scintillation counting,0.0
Binding affinity towards human AR in an in vitro assay with cellular components measured by scintillation counting,Binding affinity towards human AR in an in vitro assay with cellular components measured by scintillation counting,0.0
Binding affinity towards human CHRM2 in an in vitro assay with cellular components measured by scintillation counting,Binding affinity towards human CHRM2 in an in vitro assay with cellular components measured by scintillation counting,0.0
Binding affinity towards human DRD1 in an in vitro assay with cellular components (NIBR assay) measured by scintillation counting,Binding affinity towards human DRD1 in an in vitro assay with cellular components (NIBR assay) measured by scintillation counting,0.0
Binding affinity towards human DRD3 in an in vitro assay with cellular components measured by scintillation counting,Binding affinity towards human DRD3 in an in vitro assay with cellular components measured by scintillation counting,0.0
Binding affinity towards human ESR1 in an in vitro cell free assay (CRO assay) measured by membrane filtration,Binding affinity towards human ESR1 in an in vitro cell free assay (CRO assay) measured by membrane filtration,0.0
Binding affinity towards human HRH3 in an in vitro assay with cellular components measured by scintillation counting,Binding affinity towards human HRH3 in an in vitro assay with cellular components measured by scintillation counting,0.0
Binding affinity towards human HTR1A in an in vitro assay with cellular components measured by scintillation counting,Binding affinity towards human HTR1A in an in vitro assay with cellular components measured by scintillation counting,0.0
Binding affinity towards human OPRM1 in an in vitro assay with cellular components measured by scintillation counting,Binding affinity towards human OPRM1 in an in vitro assay with cellular components measured by scintillation counting,0.0
Binding affinity towards human PGR in an in vitro assay with cellular components measured by scintillation counting,Binding affinity towards human PGR in an in vitro assay with cellular components measured by scintillation counting,0.0
Binding affinity towards human SLC6A2 in an in vitro assay with cellular components measured by scintillation counting,Binding affinity towards human SLC6A2 in an in vitro assay with cellular components measured by scintillation counting,0.0
Binding affinity towards human SLC6A3 in an in vitro assay with cellular components measured by scintillation counting,Binding affinity towards human SLC6A3 in an in vitro assay with cellular components measured by scintillation counting,0.0
Binding affinity towards human SLC6A4 in an in vitro assay with cellular components measured by scintillation counting,Binding affinity towards human SLC6A4 in an in vitro assay with cellular components measured by scintillation counting,0.0
Biochemical firefly luciferase enzyme assay for NPC,Biochemical firefly luciferase enzyme assay for NPC,0.2256969642249772
"CYP3A4 induction through human pregnane X receptor (PXR) by small molecules, qHTS assay","CYP3A4 induction through human pregnane X receptor (PXR) by small molecules, qHTS assay",0.08300069834951432
"Caspase-3/7 induction in CHO-K1 cells by small molecules, qHTS assay: Summary","Caspase-3/7 induction in CHO-K1 cells by small molecules, qHTS assay: Summary",-0.0
"Caspase-3/7 induction in CHO-K1 cells by small molecules, qHTS cell viability counter screen","Caspase-3/7 induction in CHO-K1 cells by small molecules, qHTS cell viability counter screen",0.8968825770572165
"Caspase-3/7 induction in HepG2 cells by small molecules, qHTS assay","Caspase-3/7 induction in HepG2 cells by small molecules, qHTS assay",0.2125025611138172
"Caspase-3/7 induction in HepG2 cells by small molecules, qHTS assay: Summary","Caspase-3/7 induction in HepG2 cells by small molecules, qHTS assay: Summary",0.8050941426101431
"Caspase-3/7 induction in HepG2 cells by small molecules, qHTS cell viability counter screen","Caspase-3/7 induction in HepG2 cells by small molecules, qHTS cell viability counter screen",0.38934443360046184
Cell-based high throughput primary assay to identify activators of GPR151,Cell-based high throughput primary assay to identify activators of GPR151,0.17979616828129863
Compound was evaluated for inhibition of human ACHE in an vitro cell free assay measured by absorbance method,Compound was evaluated for inhibition of human ACHE in an vitro cell free assay measured by absorbance method,0.0
"Compound was evaluated for inhibition of human KCNH2 in an in vitro assay with cellular components measured by membrane filtration, radioactivity method","Compound was evaluated for inhibition of human KCNH2 in an in vitro assay with cellular components measured by membrane filtration, radioactivity method",0.0
Compound was evaluated for inhibition of human MAOA in an in vitro cell free assay measured by fluorescence spectroscopy,Compound was evaluated for inhibition of human MAOA in an in vitro cell free assay measured by fluorescence spectroscopy,0.0
Compound was evaluated for inhibition of human PDE3A in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,Compound was evaluated for inhibition of human PDE3A in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,0.0
Compound was evaluated for inhibition of human PDE4A in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,Compound was evaluated for inhibition of human PDE4A in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,0.0
Compound was evaluated for inhibition of human PTGS1 in an in vitro cell free assay measured by fluorescence method,Compound was evaluated for inhibition of human PTGS1 in an in vitro cell free assay measured by fluorescence method,0.0
Compound was evaluated for inhibition of human PTGS1 in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,Compound was evaluated for inhibition of human PTGS1 in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,0.0
Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,0.38019261941237875
Cytochrome P450 Family 1 Subfamily A Member 2 (CYP1A2) small molecule antagonists: luciferase reporter qHTS assay,Cytochrome P450 Family 1 Subfamily A Member 2 (CYP1A2) small molecule antagonists: luciferase reporter qHTS assay,0.8982153664307126
Cytochrome P450 Family 2 Subfamily C Member 19 (CYP2C19) small molecule antagonists: luciferase reporter qHTS assay,Cytochrome P450 Family 2 Subfamily C Member 19 (CYP2C19) small molecule antagonists: luciferase reporter qHTS assay,0.6761942220759388
Cytochrome P450 Family 2 Subfamily C Member 9 (CYP2C9) small molecule antagonists: luciferase reporter qHTS assay,Cytochrome P450 Family 2 Subfamily C Member 9 (CYP2C9) small molecule antagonists: luciferase reporter qHTS assay,1.0
Cytochrome P450 Family 2 Subfamily D Member 6 (CYP2D6) small molecule antagonists: luciferase reporter qHTS assay,Cytochrome P450 Family 2 Subfamily D Member 6 (CYP2D6) small molecule antagonists: luciferase reporter qHTS assay,0.2870030868784649
Cytochrome P450 Family 3 Subfamily A Member 4 (CYP3A4) small molecule antagonists: luciferase reporter qHTS assay,Cytochrome P450 Family 3 Subfamily A Member 4 (CYP3A4) small molecule antagonists: luciferase reporter qHTS assay,0.8479524370598133
Cytochrome P450 family 2 subfamily C member 9 (CYP2C9) small molecule antagonists: luciferase cell-based qHTS assay,Cytochrome P450 family 2 subfamily C member 9 (CYP2C9) small molecule antagonists: luciferase cell-based qHTS assay,1.0
Cytochrome P450 family 2 subfamily D member 6 (CYP2D6) small molecule antagonists: luciferase cell-based qHTS assay,Cytochrome P450 family 2 subfamily D member 6 (CYP2D6) small molecule antagonists: luciferase cell-based qHTS assay,0.06802205513636442
Cytochrome P450 family 3 subfamily A member 4 (CYP3A4) small molecule antagonists: luciferase cell-based qHTS assay,Cytochrome P450 family 3 subfamily A member 4 (CYP3A4) small molecule antagonists: luciferase cell-based qHTS assay,0.9389038039295036
Cytochrome P450 family 3 subfamily A member 7 (CYP3A7) small molecule antagonists: luciferase cell-based qHTS assay,Cytochrome P450 family 3 subfamily A member 7 (CYP3A7) small molecule antagonists: luciferase cell-based qHTS assay,1.0
Cytochrome panel assay with activity outcomes,Cytochrome panel assay with activity outcomes,0.06127385571001668
Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening,Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening,0.24784517214054083
Cytotoxicity counterscreen for inhibitors of SARS-CoV-2 cell entry,Cytotoxicity counterscreen for inhibitors of SARS-CoV-2 cell entry,0.6145570994497375
DLD viability from Cell TiterGlo-screen,DLD viability from Cell TiterGlo-screen,0.46468098342401964
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,0.0
Dicer-mediated maturation of pre-microRNA,Dicer-mediated maturation of pre-microRNA,-0.0
Drug repurposing screens with cells derived from glioblastoma tumor samples,Drug repurposing screens with cells derived from glioblastoma tumor samples,0.20260419792671253
ERK5 transcriptional activity HTS,ERK5 transcriptional activity HTS,-0.0
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),0.12735609682553004
"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)","Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",0.0403179714647476
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),0.15561969712862056
"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)","Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",0.12267945499594059
"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)","Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",0.20286273120063214
GLP1 secretion from NCI-H716 cells-screen,GLP1 secretion from NCI-H716 cells-screen,0.28571915302583134
GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,0.4496268046574017
HCT116 viability from Cell TiterGlo-screen,HCT116 viability from Cell TiterGlo-screen,0.4302049065271789
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,0.07042607457527562
HTS Assay for Peg3 Promoter Inhibitors,HTS Assay for Peg3 Promoter Inhibitors,0.06643469651421298
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,0.33215676111379483
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,-0.0
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,0.4406845109824383
High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,0.512573284310018
High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,0.23392004060453542
Human Ether-a-go-go-Related Gene (hERG) channel small molecule antagonists: fluorescence cell-based qHTS assay,Human Ether-a-go-go-Related Gene (hERG) channel small molecule antagonists: fluorescence cell-based qHTS assay,0.13847959708739224
"Human gonadotropin-releasing hormone receptor (GnRHR) small molecule agonists, calcium flux assay in GnRHR-HEK293 cells","Human gonadotropin-releasing hormone receptor (GnRHR) small molecule agonists, calcium flux assay in GnRHR-HEK293 cells",0.23199243621037666
"Human pregnane X receptor (PXR) activation by small molecules, qHTS assay","Human pregnane X receptor (PXR) activation by small molecules, qHTS assay",-0.0
"Human pregnane X receptor (PXR) small molecule agonists, qHTS assay","Human pregnane X receptor (PXR) small molecule agonists, qHTS assay",0.11460285006809198
"Human pregnane X receptor (PXR) small molecule agonists, qHTS cell viability counter screen","Human pregnane X receptor (PXR) small molecule agonists, qHTS cell viability counter screen",0.25973435432636977
Human pregnane X receptor (PXR) small molecule agonists: Summary,Human pregnane X receptor (PXR) small molecule agonists: Summary,0.4317601306881688
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,0.08095577325318669
In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,0.03374849423411547
Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method,Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method,0.0
Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,0.02954444982245245
Inhibitors of USP1/UAF1: Pilot qHTS,Inhibitors of USP1/UAF1: Pilot qHTS,0.223851231261094
Inhibitors of the vitamin D receptor (VDR): qHTS,Inhibitors of the vitamin D receptor (VDR): qHTS,0.34499879823368945
Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,-0.0
Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,-0.0
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.,Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.,0.18114373555739258
MELAS cybrid survival enhancement under low glucose conditions,MELAS cybrid survival enhancement under low glucose conditions,-0.0
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,0.07812643031756966
NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,0.10661047224329492
NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,-0.0
NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,0.051679770116970385
NCI Yeast Anticancer Drug Screen. Data for the mec2 strain,NCI Yeast Anticancer Drug Screen. Data for the mec2 strain,0.06085118926416364
NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,0.023982690141082823
NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,0.03846795715110637
NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,0.011373392205977441
"NCI human tumor cell line growth inhibition assay. Data for the 786-0 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the 786-0 Non-Small Cell Lung cell line, single concentration",0.12200820877780122
"NCI human tumor cell line growth inhibition assay. Data for the A498 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the A498 Non-Small Cell Lung cell line, single concentration",0.026458950984418774
"NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line, single concentration",0.08708555580925077
"NCI human tumor cell line growth inhibition assay. Data for the ACHN Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the ACHN Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the BT-549 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the BT-549 Non-Small Cell Lung cell line, single concentration",0.34821261319827673
"NCI human tumor cell line growth inhibition assay. Data for the CAKI Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the CAKI Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Non-Small Cell Lung cell line, single concentration",0.17124051468733875
"NCI human tumor cell line growth inhibition assay. Data for the DU45 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the DU45 Non-Small Cell Lung cell line, single concentration",0.13185890458791966
"NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Non-Small Cell Lung cell line, single concentration",0.02571006818834622
"NCI human tumor cell line growth inhibition assay. Data for the HCT16 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the HCT16 Non-Small Cell Lung cell line, single concentration",0.2568096704710653
"NCI human tumor cell line growth inhibition assay. Data for the HCT5 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the HCT5 Non-Small Cell Lung cell line, single concentration",0.15454098292492946
"NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Non-Small Cell Lung cell line, single concentration",0.3322498977599087
"NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line, single concentration",0.021444548061140118
"NCI human tumor cell line growth inhibition assay. Data for the HS 578T Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the HS 578T Non-Small Cell Lung cell line, single concentration",0.03722613314967209
"NCI human tumor cell line growth inhibition assay. Data for the HT29 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the HT29 Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Non-Small Cell Lung cell line, single concentration",0.24318356938428595
"NCI human tumor cell line growth inhibition assay. Data for the K-562 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the K-562 Non-Small Cell Lung cell line, single concentration",0.05277412512996469
"NCI human tumor cell line growth inhibition assay. Data for the KM12 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the KM12 Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Non-Small Cell Lung cell line, single concentration",0.028301524732653287
"NCI human tumor cell line growth inhibition assay. Data for the M14 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the M14 Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Non-Small Cell Lung cell line, single concentration",0.17483754445867225
"NCI human tumor cell line growth inhibition assay. Data for the MCF7 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the MCF7 Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Non-Small Cell Lung cell line, single concentration",0.03307796434914769
"NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Non-Small Cell Lung cell line, single concentration",0.029928862454075618
"NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Non-Small Cell Lung cell line, single concentration",0.2786738321848459
"NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line, single concentration",0.09373257410009887
"NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line, single concentration",0.0999329489095457
"NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line, single concentration",0.02336387863821383
"NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Non-Small Cell Lung cell line, single concentration",0.16478330152523574
"NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the PC-3 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the PC-3 Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the SF-295 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the SF-295 Non-Small Cell Lung cell line, single concentration",0.204388166989729
"NCI human tumor cell line growth inhibition assay. Data for the SF-539 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the SF-539 Non-Small Cell Lung cell line, single concentration",0.05828509250851969
"NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Non-Small Cell Lung cell line, single concentration",0.08005777940680744
"NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Non-Small Cell Lung cell line, single concentration",0.08788641818717573
"NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Non-Small Cell Lung cell line, single concentration",0.07995816537518073
"NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Non-Small Cell Lung cell line, single concentration",0.07917270504427049
"NCI human tumor cell line growth inhibition assay. Data for the SR Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the SR Non-Small Cell Lung cell line, single concentration",0.02047808980619869
"NCI human tumor cell line growth inhibition assay. Data for the SW-620 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the SW-620 Non-Small Cell Lung cell line, single concentration",0.04041358765369153
"NCI human tumor cell line growth inhibition assay. Data for the T-47D Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the T-47D Non-Small Cell Lung cell line, single concentration",0.06954801613804432
"NCI human tumor cell line growth inhibition assay. Data for the TK0 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the TK0 Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the U251 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the U251 Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Non-Small Cell Lung cell line, single concentration",-0.0
"NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Non-Small Cell Lung cell line, single concentration",0.02947356630312003
"NCI human tumor cell line growth inhibition assay. Data for the UO-31 Non-Small Cell Lung cell line, single concentration","NCI human tumor cell line growth inhibition assay. Data for the UO-31 Non-Small Cell Lung cell line, single concentration",0.03649606138533065
NS1 protein of Zika virus - qHTS assay to identify small molecule inhibitors in human HEK 293 cells,NS1 protein of Zika virus - qHTS assay to identify small molecule inhibitors in human HEK 293 cells,0.051854450843884084
Nrf2 qHTS screen for inhibitors,Nrf2 qHTS screen for inhibitors,0.3043571122746619
"Nuclear factor erythroid 2-related factor 2/antioxidant responsive element (Nrf2/ARE) small molecule agonists, luciferase reporter gene qHTS assay in human keratinocytes: Summary","Nuclear factor erythroid 2-related factor 2/antioxidant responsive element (Nrf2/ARE) small molecule agonists, luciferase reporter gene qHTS assay in human keratinocytes: Summary",0.08019792234436383
Nuclear factor erythroid 2-related factor 2/antioxidant responsive element (Nrf2/ARE) small molecule agonists: luciferase reporter gene qHTS assay in human keratinocytes,Nuclear factor erythroid 2-related factor 2/antioxidant responsive element (Nrf2/ARE) small molecule agonists: luciferase reporter gene qHTS assay in human keratinocytes,0.08531087556505249
Nuclear factor erythroid 2-related factor 2/antioxidant responsive element (Nrf2/ARE) small molecule agonists: qHTS cell viability counter screen in human keratinocytes,Nuclear factor erythroid 2-related factor 2/antioxidant responsive element (Nrf2/ARE) small molecule agonists: qHTS cell viability counter screen in human keratinocytes,0.16636936829743953
"P-glycoprotein substrates identified in KB-3 adenocarcinoma cell line, qHTS therapeutic library screen","P-glycoprotein substrates identified in KB-3 adenocarcinoma cell line, qHTS therapeutic library screen",0.2926842894728771
"P-glycoprotein substrates identified in KB-8-51 adenocarcinoma cell line, qHTS therapeutic library screen","P-glycoprotein substrates identified in KB-8-51 adenocarcinoma cell line, qHTS therapeutic library screen",0.2323859776365632
Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),-0.0
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),0.037081435347838636
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),0.04282096432662462
Primary qHTS Assay for Inhibitors of Recombinant Selenoprotein Glutathione Peroxidase 1 (GPX1),Primary qHTS Assay for Inhibitors of Recombinant Selenoprotein Glutathione Peroxidase 1 (GPX1),0.39750912487813156
Primary qHTS Assay for Inhibitors of Recombinant Selenoprotein Glutathione Peroxidase 4 (GPX4),Primary qHTS Assay for Inhibitors of Recombinant Selenoprotein Glutathione Peroxidase 4 (GPX4),0.2809299319004781
Primary qHTS assay for inhibitors of Glutamate pyruvate transaminase 2 (GPT2),Primary qHTS assay for inhibitors of Glutamate pyruvate transaminase 2 (GPT2),-0.0
Primary qHTS for Inhibitors of ATXN expression,Primary qHTS for Inhibitors of ATXN expression,0.16647176735946584
Primary qHTS for Inhibitors of N-terminal methyltransferase 1 (NTMT1): MTaseGlo Assay,Primary qHTS for Inhibitors of N-terminal methyltransferase 1 (NTMT1): MTaseGlo Assay,0.20423142279872067
"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation","Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",0.10297706712040103
"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation","Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",-0.0
Primary qHTS for inhibitors of MERS-S pseudo-typed particle cell entry,Primary qHTS for inhibitors of MERS-S pseudo-typed particle cell entry,0.03490706448286824
Primary qHTS for inhibitors of SARS-S pseudo-typed particle cell entry,Primary qHTS for inhibitors of SARS-S pseudo-typed particle cell entry,-0.0
Primary qHTS for inhibitors of nuclear receptor binding SET domain protein 2 (NSD2) in an RCH-ACV wild type WT cells (2C),Primary qHTS for inhibitors of nuclear receptor binding SET domain protein 2 (NSD2) in an RCH-ACV wild type WT cells (2C),0.4081712935707693
Primary qHTS for inhibitors of nuclear receptor binding SET domain protein 2 (NSD2) in an isogenic RCH-ACV NSD2 p.E1099K mutant (9B),Primary qHTS for inhibitors of nuclear receptor binding SET domain protein 2 (NSD2) in an isogenic RCH-ACV NSD2 p.E1099K mutant (9B),0.6563552329290575
Primary qHTS to identify gynecologic anti-cancer compounds using libraries of approved drugs and bioactive compounds,Primary qHTS to identify gynecologic anti-cancer compounds using libraries of approved drugs and bioactive compounds,0.4807417024743249
Primary qHTS to identify inhibitors of SARS-CoV-2 cell entry,Primary qHTS to identify inhibitors of SARS-CoV-2 cell entry,0.1588288610795278
Primary screen GU AMC qHTS for Zika virus inhibitors,Primary screen GU AMC qHTS for Zika virus inhibitors,0.21832927528804685
"Progesterone receptor (PR) small molecule agonists, qHTS assay: Summary","Progesterone receptor (PR) small molecule agonists, qHTS assay: Summary",-0.0
"Progesterone receptor (PR) small molecule antagonists, qHTS assay: Summary","Progesterone receptor (PR) small molecule antagonists, qHTS assay: Summary",0.5036739291634259
Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,0.0
Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),0.0
Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),0.0
Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),0.0
Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),0.0
"Rat pregnane X receptor (rPXR) activation by small molecules, qHTS assay","Rat pregnane X receptor (rPXR) activation by small molecules, qHTS assay",-0.0
S16 Schwann cell PMP22 intronic element beta-lactamase assay,S16 Schwann cell PMP22 intronic element beta-lactamase assay,0.0878243606640667
S16 Schwann cell PMP22 intronic element firefly luciferase assay,S16 Schwann cell PMP22 intronic element firefly luciferase assay,0.040215632281148536
S16 Schwann cell viability assay (CellTiter-Glo assay),S16 Schwann cell viability assay (CellTiter-Glo assay),0.03318626615296223
SW480 viability from Cell TiterGlo-screen,SW480 viability from Cell TiterGlo-screen,0.4474098953815152
Screen for inhibitors of RMI FANCM (MM2) intereaction,Screen for inhibitors of RMI FANCM (MM2) intereaction,-0.0
"TGF-beta/Smad small molecule antagonists, qHTS assay: Summary","TGF-beta/Smad small molecule antagonists, qHTS assay: Summary",0.083420948395007
"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395","The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",0.2995311055915471
Toxoplasma gondii HTS in the absence of IFN-y,Toxoplasma gondii HTS in the absence of IFN-y,0.6666766654908841
Toxoplasma gondii inhibition HTS in the presence of IFN-y,Toxoplasma gondii inhibition HTS in the presence of IFN-y,1.0
VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,0.3599889460646083
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,0.12266782991454629
Validation qHTS for antagonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2),Validation qHTS for antagonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2),0.05803361833766301
Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression,Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression,0.2964812207408485
insulin secretion from INSE cells in the presence of 5 mM glucose-screen,insulin secretion from INSE cells in the presence of 5 mM glucose-screen,-0.0
mouse cGAS RapidFire screen,mouse cGAS RapidFire screen,0.2457054348193734
nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,0.23609761749656935
p450-cyp1a2,p450-cyp1a2,0.13661646534523494
"p53 small molecule agonists, cell-based qHTS assay","p53 small molecule agonists, cell-based qHTS assay",0.49435811540810803
"p53 small molecule agonists, cell-based qHTS assay with human liver microsomes: qHTS cell viability counter screen","p53 small molecule agonists, cell-based qHTS assay with human liver microsomes: qHTS cell viability counter screen",-0.0
"p53 small molecule agonists, cell-based qHTS assay with rat liver microsomes: qHTS cell viability counter screen","p53 small molecule agonists, cell-based qHTS assay with rat liver microsomes: qHTS cell viability counter screen",0.04837263885235535
"p53 small molecule agonists, cell-based qHTS assay: Summary","p53 small molecule agonists, cell-based qHTS assay: Summary",0.4268978325181686
"p53 small molecule agonists, cell-based qHTS assay: qHTS cell viability counter screen","p53 small molecule agonists, cell-based qHTS assay: qHTS cell viability counter screen",0.0970584990374786
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,0.09191112229053777
qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,0.06948238861641581
"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel","qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",0.13482158151644646
"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel","qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",0.12677558002897135
"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel","qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",0.08103112782079687
qHTS Assay for Identifying Gametocytocidal Compounds,qHTS Assay for Identifying Gametocytocidal Compounds,-0.0
qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,-0.0
qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,0.0847491891516756
qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,0.18500727580793033
qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,0.04843157800122475
qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),0.07720225315824818
qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),-0.0
qHTS Assay for Inhibitors of BAZ2B,qHTS Assay for Inhibitors of BAZ2B,0.3617045183547419
qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),0.03336869327802989
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),0.26731816019992743
"qHTS Assay for Inhibitors of Fructose,6-bisphosphate Aldolase from Giardia Lamblia","qHTS Assay for Inhibitors of Fructose,6-bisphosphate Aldolase from Giardia Lamblia",0.2719769339497469
qHTS Assay for Inhibitors of GCN5L2,qHTS Assay for Inhibitors of GCN5L2,0.6993041903849352
"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)","qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",-0.0
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),0.9318889616495968
"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4","qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",-0.0
qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),0.11321001208577762
qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,0.08029539029083096
qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,0.04153500629197352
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,0.11480899986290374
qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),0.6536982041325062
qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),0.6205948677608663
qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,0.27320261129090506
qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,0.01614002873170876
qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,0.015394813629826726
qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),0.12612821000295665
qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,0.1686973685317045
qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,0.1412052790063209
qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,-0.0
qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,0.1411936231066387
qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,0.3763303449453656
qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,0.4549008994737828
qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,0.050694790848607556
qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,0.07677341832100056
qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,0.10869883338295089
qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,0.10341487060231529
qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,0.25718421067447766
qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,0.03156349288930985
qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,0.07627861877975789
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,0.06086585142237675
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1,qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1,0.09781856442436769
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3,qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3,-0.0
qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,0.24454226335323936
qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,0.24225935003678914
qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,0.07080524569447175
qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,-0.0
qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,0.5875722809967595
qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,0.36267695295755575
qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,0.12151467765439287
qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,0.775973915724978
qHTS assay for small molecule agonists of the p53 signaling pathway,qHTS assay for small molecule agonists of the p53 signaling pathway,0.3040363131977439
qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,0.35444940281182896
qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,0.40474232651358305
qHTS assay for small molecule disruptors of the mitochondrial membrane potential,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,0.44785308129045864
qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,0.8772289944275414
qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,0.5901058629295554
qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,-0.0
qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,0.10855798782070714
qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,-0.0
qHTS assay to identify aromatase inhibitors,qHTS assay to identify aromatase inhibitors,-0.0
qHTS assay to identify aromatase inhibitors - cell viability counter screen,qHTS assay to identify aromatase inhibitors - cell viability counter screen,0.44269624961831855
qHTS assay to identify aromatase inhibitors: Summary,qHTS assay to identify aromatase inhibitors: Summary,0.17858845034520235
qHTS assay to identify novel small-molecules to repurpose for Merkel cell carcinoma treatment,qHTS assay to identify novel small-molecules to repurpose for Merkel cell carcinoma treatment,0.5298738663630427
qHTS assay to identify small molecule HDAC inhibitors,qHTS assay to identify small molecule HDAC inhibitors,0.05659224059523394
qHTS assay to identify small molecule HDAC inhibitors: Summary,qHTS assay to identify small molecule HDAC inhibitors: Summary,0.1532056206121644
qHTS assay to identify small molecule agonists of H2AX,qHTS assay to identify small molecule agonists of H2AX,0.17142361300467296
qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,0.11972877926185535
qHTS assay to identify small molecule agonists of H2AX: Summary,qHTS assay to identify small molecule agonists of H2AX: Summary,0.5824783817882017
qHTS assay to identify small molecule agonists of the AP signaling pathway - cell viability counter screen,qHTS assay to identify small molecule agonists of the AP signaling pathway - cell viability counter screen,0.2951146087123687
qHTS assay to identify small molecule agonists of the AP signaling pathway: Summary,qHTS assay to identify small molecule agonists of the AP signaling pathway: Summary,0.12356023361006573
qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,0.12402021019642746
qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,0.2668005070753446
qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,0.12646785118602327
qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,0.06086390087120847
qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,0.0783745210931566
qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,0.07062834323535032
qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,-0.0
qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,0.07037252905751622
qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,0.0661602478757821
qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,0.2763724607893944
qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,0.33890250781761605
qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,0.08684872561549464
qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,0.03631863404366944
qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,0.10752292007626087
qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,0.4093517817208767
qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,-0.0
qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,0.6380946416901659
qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,0.17141979166714058
qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,0.10752292007626087
qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,0.7907288816391017
qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,0.27764661248117317
qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,0.8031397827997199
qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,0.30188953375435934
qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,0.3113249687509038
qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,0.34826354566773926
qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,0.29640849739945757
qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,-0.0
qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,0.05328760709253427
qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,-0.0
qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,-0.0
qHTS assay to identify small molecule agonists of the hypoxia (HIF) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule agonists of the hypoxia (HIF) signaling pathway - cell viability counter screen,0.023275979466161206
qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,0.022150993238438853
qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,0.8717432276892491
qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,1.0
qHTS assay to identify small molecule agonists of the progesterone receptor (PR) signaling pathway,qHTS assay to identify small molecule agonists of the progesterone receptor (PR) signaling pathway,-0.0
qHTS assay to identify small molecule agonists of the progesterone receptor (PR) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule agonists of the progesterone receptor (PR) signaling pathway - cell viability counter screen,0.43933526307598847
qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,0.7372244243972895
qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,0.40756673975319874
qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,0.3337277219932511
qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,0.23314133979684362
qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,0.026611232537638297
qHTS assay to identify small molecule antagonists of the TGF-beta/Smad signaling pathway - cell viability counter screen,qHTS assay to identify small molecule antagonists of the TGF-beta/Smad signaling pathway - cell viability counter screen,0.05951250571160021
qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,0.24977119553513258
qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,0.27115252970658826
qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,0.058435503439006845
qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,0.2764237251192021
qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,0.23985621804048157
qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,0.13845978331171224
qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,0.5165798340517942
qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,0.7853530242076483
qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,0.8789034282365233
qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,0.2679029552370699
qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,0.09906303826015464
qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,0.28723134036446835
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,0.35966094781919705
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,0.04759507742509108
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,0.1433235946138153
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,0.10311170441167612
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,0.07956363557885604
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,0.16352955835161623
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,0.13999712509717815
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,0.1433235946138153
qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,0.35966094781919705
qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,0.20031868891985052
qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,0.4799679179958076
qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,0.4622429087650958
qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,1.0
qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,0.6567051915438622
qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,0.5985223714455218
qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,0.573004553478921
qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,0.09540952190409446
qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,0.28825138049464794
qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,0.14324787673480754
qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,0.32000405522542613
qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,0.31845968433897087
qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,0.3075271494403588
qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,0.10126206509362716
qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,0.6736132509229089
qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,0.721958252689788
qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,-0.0
qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,0.04915415731126125
qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,0.12935089324658136
qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,0.723742555104383
qHTS assay to identify small molecule antagonists of the progesterone receptor (PR) signaling pathway,qHTS assay to identify small molecule antagonists of the progesterone receptor (PR) signaling pathway,0.7124047554021973
qHTS assay to identify small molecule antagonists of the progesterone receptor (PR) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule antagonists of the progesterone receptor (PR) signaling pathway - cell viability counter screen,0.4433849464053553
qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway ,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway ,0.5306169495383286
qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,0.49737833370227064
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway ,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway ,0.46504982357365227
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,-0.0
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,0.44358955039064374
qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,0.9676899029691125
qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,0.43638255248343866
qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,0.04977291308968256
qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,0.776013208812599
qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,0.10794719120462948
qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,0.749946816549897
qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,-0.0
qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,0.31511812723740756
qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,-0.0
qHTS assay to identify small molecule inhibitors of chordoma cells - UCH,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH,0.08341818300999619
qHTS assay to identify small molecule inhibitors of firefly luciferase,qHTS assay to identify small molecule inhibitors of firefly luciferase,0.851102909952573
qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,0.20662629940059574
qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,0.08709610207553158
qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,0.3806294141652968
qHTS for Agonists of Human Resolvin D1 Receptor DRV1,qHTS for Agonists of Human Resolvin D1 Receptor DRV1,-0.0
qHTS for Inhibitors of Inflammasome Signaling:  IL-beta AlphaLISA Primary Screen,qHTS for Inhibitors of Inflammasome Signaling:  IL-beta AlphaLISA Primary Screen,0.11580976479164537
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,0.1728389101850775
qHTS for Inhibitors of Polymerase Eta,qHTS for Inhibitors of Polymerase Eta,0.1558454644076845
qHTS for Inhibitors of Polymerase Iota,qHTS for Inhibitors of Polymerase Iota,-0.0
qHTS for Inhibitors of Polymerase Kappa,qHTS for Inhibitors of Polymerase Kappa,0.057748732885443924
qHTS for Inhibitors of TGF-b,qHTS for Inhibitors of TGF-b,0.08148737098450148
qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,0.29512182864804953
"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding","qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",0.0636789702854192
qHTS for Inhibitors of binding or entry into cells for Lassa Virus,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,0.23529637383411364
qHTS for Inhibitors of binding or entry into cells for Marburg Virus,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,0.5149570992291679
qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,0.17682956722735393
qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,0.10437472924525723
qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen,qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen,0.3761812609260607
qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal,qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal,0.4091019587893792
qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - alamar blue signal for LCMV Primary Screen,qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - alamar blue signal for LCMV Primary Screen,-0.0
qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT080-IDH1KD cell line,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT080-IDH1KD cell line,0.2869661228576434
qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT080-NT fibrosarcoma cell line,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT080-NT fibrosarcoma cell line,0.0665231074114348
qHTS for inhibitors of ROR gamma transcriptional activity,qHTS for inhibitors of ROR gamma transcriptional activity,0.11145495287187064
qHTS of D3 Dopamine Receptor Agonist: qHTS,qHTS of D3 Dopamine Receptor Agonist: qHTS,1.0
qHTS of D3 Dopamine Receptor Antagonist: qHTS,qHTS of D3 Dopamine Receptor Antagonist: qHTS,0.11454076954457659
qHTS of D3 Dopamine Receptor Potentiators: qHTS,qHTS of D3 Dopamine Receptor Potentiators: qHTS,1.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells,0.16089914567932717
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT2 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT2 cells,0.31541392527719236
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells,0.13745051002064396
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells,0.5679125960275436
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells,0.022437884555520142
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells,0.02534598969837178
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells,-0.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells,-0.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells,0.2140391737088597
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells,-0.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells,0.029690593796019335
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells,0.06579703127023892
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells,0.023182380818389345
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells,0.31055336441896253
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells,0.0965383226649698
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells,0.3806382563791294
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells,-0.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells,0.16422887013539078
qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),0.24418370686863639
qHTS profiling for inhibitors of Plasmodium falciparum proliferation,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,0.2952380782521335
uHTS Fluorescent assay for identification of inhibitors of Apaf,uHTS Fluorescent assay for identification of inhibitors of Apaf,0.08432359157743595
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,0.021436325215535804
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,0.24554751962846172
uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,0.06747792896955676
A qHTS for Small Molecule Inhibitors of Shiga Toxin,A qHTS for Small Molecule Inhibitors of Shiga Toxin,0.14397378959838902
Agonist activity at human ADRA1A in an in vitro cell-based assay (NIBR assay) measured by fluorescent imaging plate reader,Agonist activity at human ADRA1A in an in vitro cell-based assay (NIBR assay) measured by fluorescent imaging plate reader,0.0
Agonist activity at human ADRA2A in an in vitro cell-based assay measured by fluorescent imaging plate reader,Agonist activity at human ADRA2A in an in vitro cell-based assay measured by fluorescent imaging plate reader,0.0
Agonist activity at human DRD1 in an in vitro cell-based assay measured by time-resolved fluorescence resonance energy transfer method,Agonist activity at human DRD1 in an in vitro cell-based assay measured by time-resolved fluorescence resonance energy transfer method,0.0
Agonist activity at human HTR1A in an in vitro cell-based assay measured by fluorescent imaging plate reader,Agonist activity at human HTR1A in an in vitro cell-based assay measured by fluorescent imaging plate reader,0.0
Agonist activity at human NR1I2 in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,Agonist activity at human NR1I2 in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,0.0
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of Unc-51 Like Autophagy Activating Kinase 1 (ULK1).,AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of Unc-51 Like Autophagy Activating Kinase 1 (ULK1).,0.6075240699852469
Antagonist activity at human ADRA2A in an in vitro cell-based assay measured by fluorescent imaging plate reader,Antagonist activity at human ADRA2A in an in vitro cell-based assay measured by fluorescent imaging plate reader,0.0
Antagonist activity at human CHRM2 in an in vitro cell-based assay measured by fluorescent imaging plate reader,Antagonist activity at human CHRM2 in an in vitro cell-based assay measured by fluorescent imaging plate reader,0.0
Antagonist activity at human HRH1 in an in vitro cell-based assay measured by fluorescent imaging plate reader,Antagonist activity at human HRH1 in an in vitro cell-based assay measured by fluorescent imaging plate reader,0.0
Antagonist activity at human HTR1A in an in vitro cell-based assay measured by fluorescent imaging plate reader,Antagonist activity at human HTR1A in an in vitro cell-based assay measured by fluorescent imaging plate reader,0.0
Antagonist activity at human HTR2A in an in vitro cell-based assay measured by fluorescent imaging plate reader,Antagonist activity at human HTR2A in an in vitro cell-based assay measured by fluorescent imaging plate reader,0.0
Antagonist activity at human HTR2B in an in vitro cell-based assay measured by fluorescent imaging plate reader,Antagonist activity at human HTR2B in an in vitro cell-based assay measured by fluorescent imaging plate reader,0.0
Binding affinity towards human ADORA3 in an in vitro assay with cellular components measured by scintillation proximity assay,Binding affinity towards human ADORA3 in an in vitro assay with cellular components measured by scintillation proximity assay,0.0
Binding affinity towards human ADRA1A in an in vitro assay with cellular components (NIBR assay) measured by scintillation proximity assay,Binding affinity towards human ADRA1A in an in vitro assay with cellular components (NIBR assay) measured by scintillation proximity assay,0.0
Binding affinity towards human ADRA2B in an in vitro assay with cellular components measured by scintillation proximity assay,Binding affinity towards human ADRA2B in an in vitro assay with cellular components measured by scintillation proximity assay,0.0
Binding affinity towards human ADRB2 in an in vitro assay with cellular components measured by radioactivity method,Binding affinity towards human ADRB2 in an in vitro assay with cellular components measured by radioactivity method,0.0
Binding affinity towards human ADRB3 in an in vitro assay with cellular components measured by scintillation proximity assay,Binding affinity towards human ADRB3 in an in vitro assay with cellular components measured by scintillation proximity assay,0.0
Binding affinity towards human AGTR1 in an in vitro assay with cellular components measured by scintillation proximity assay,Binding affinity towards human AGTR1 in an in vitro assay with cellular components measured by scintillation proximity assay,0.0
Binding affinity towards human CHRM3 in an in vitro assay with cellular components measured by scintillation proximity assay,Binding affinity towards human CHRM3 in an in vitro assay with cellular components measured by scintillation proximity assay,0.0
Binding affinity towards human CNR1 in an in vitro assay with cellular components measured by membrane filtration,Binding affinity towards human CNR1 in an in vitro assay with cellular components measured by membrane filtration,0.0
"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay","Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",0.0
Binding affinity towards human ESR1 in an in vitro cell free assay (NIBR assay) measured by fluorescence polarization method,Binding affinity towards human ESR1 in an in vitro cell free assay (NIBR assay) measured by fluorescence polarization method,0.0
Binding affinity towards human GHSR in an in vitro assay with cellular components measured by scintillation proximity assay,Binding affinity towards human GHSR in an in vitro assay with cellular components measured by scintillation proximity assay,0.0
Binding affinity towards human HRH1 in an in vitro assay measured by filtration,Binding affinity towards human HRH1 in an in vitro assay measured by filtration,0.0
Binding affinity towards human HRH2 in an in vitro assay with cellular components measured by membrane filtration,Binding affinity towards human HRH2 in an in vitro assay with cellular components measured by membrane filtration,0.0
Binding affinity towards human HTR2A in an in vitro assay with cellular components measured by membrane filtration,Binding affinity towards human HTR2A in an in vitro assay with cellular components measured by membrane filtration,0.0
Binding affinity towards human HTR2B in an in vitro assay with cellular components measured by membrane filtration,Binding affinity towards human HTR2B in an in vitro assay with cellular components measured by membrane filtration,0.0
Binding affinity towards human HTR2C in an in vitro assay with cellular components measured by radioactivity method,Binding affinity towards human HTR2C in an in vitro assay with cellular components measured by radioactivity method,0.0
Binding affinity towards human MC3R in an in vitro assay with cellular components measured by scintillation proximity assay,Binding affinity towards human MC3R in an in vitro assay with cellular components measured by scintillation proximity assay,0.0
Binding affinity towards human MLNR in an in vitro assay with cellular components measured by scintillation proximity assay,Binding affinity towards human MLNR in an in vitro assay with cellular components measured by scintillation proximity assay,0.0
"Binding affinity towards human NR3C1 in an in vitro cell free assay measured by filtration, radioactivity method","Binding affinity towards human NR3C1 in an in vitro cell free assay measured by filtration, radioactivity method",0.0
Binding affinity towards human OPRD1 in an in vitro assay with cellular components measured by scintillation proximity assay,Binding affinity towards human OPRD1 in an in vitro assay with cellular components measured by scintillation proximity assay,0.0
"Binding affinity towards human OPRK1 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay","Binding affinity towards human OPRK1 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",0.0
Binding affinity towards rat Ar in an in vitro cell free assay measured by fluorescence polarization method,Binding affinity towards rat Ar in an in vitro cell free assay measured by fluorescence polarization method,0.0
CCRIS mutagenicity studies,CCRIS mutagenicity studies,0.1415148819701421
"Compound was evaluated for inhibition of human ABCB11 in an in vitro assay with cellular components measured by filtration, liquid scintillation counting","Compound was evaluated for inhibition of human ABCB11 in an in vitro assay with cellular components measured by filtration, liquid scintillation counting",0.0
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration,Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration,0.0
Compound was evaluated for inhibition of human ADRB1 in an in vitro assay measured by radioactivity method,Compound was evaluated for inhibition of human ADRB1 in an in vitro assay measured by radioactivity method,0.0
Compound was evaluated for inhibition of human CHRM1 in an in vitro assay with cellular components measured by scintillation proximity assay,Compound was evaluated for inhibition of human CHRM1 in an in vitro assay with cellular components measured by scintillation proximity assay,0.0
"Compound was evaluated for inhibition of human HTR3A in an in vitro assay with cellular components measured by membrane filtration, radioactivity method","Compound was evaluated for inhibition of human HTR3A in an in vitro assay with cellular components measured by membrane filtration, radioactivity method",0.0
Compound was evaluated for inhibition of human PDE4D in an in vitro cell free assay measured by scintillation proximity assay,Compound was evaluated for inhibition of human PDE4D in an in vitro cell free assay measured by scintillation proximity assay,0.0
Compound was evaluated for inhibition of human PTGS2 in an in vitro cell free assay measured by fluorescence spectroscopy,Compound was evaluated for inhibition of human PTGS2 in an in vitro cell free assay measured by fluorescence spectroscopy,0.0
Compound was evaluated for inhibition of rat Cacna1c in an in vitro assay with cellular components measured by membrane filtration,Compound was evaluated for inhibition of rat Cacna1c in an in vitro assay with cellular components measured by membrane filtration,0.0
Compound was evaluated for inhibition of rat Gabra1 in an in vitro assay with cellular components measured by membrane filtration,Compound was evaluated for inhibition of rat Gabra1 in an in vitro assay with cellular components measured by membrane filtration,0.0
Compound was evaluated for inhibition of rat Ptgs1 in an in vitro cell free assay measured by fluorescence spectroscopy,Compound was evaluated for inhibition of rat Ptgs1 in an in vitro cell free assay measured by fluorescence spectroscopy,0.0
Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,0.0
DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),0.0
DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),0.0
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),0.0
DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),0.0
DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP2177),DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP2177),0.0
DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),0.0
DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),0.0
DRUGMATRIX: AlphaA adrenergic receptor radioligand binding (ligand: prazosin),DRUGMATRIX: AlphaA adrenergic receptor radioligand binding (ligand: prazosin),0.0
DRUGMATRIX: AlphaB adrenergic receptor radioligand binding (ligand: prazosin),DRUGMATRIX: AlphaB adrenergic receptor radioligand binding (ligand: prazosin),0.0
DRUGMATRIX: AlphaD adrenergic receptor radioligand binding (ligand: prazosin),DRUGMATRIX: AlphaD adrenergic receptor radioligand binding (ligand: prazosin),0.0
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),0.0
DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),0.0
DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),0.0
"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)","DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",0.0
"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)","DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",0.0
"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)","DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",0.0
"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)","DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",0.0
"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)","DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",0.0
"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)","DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",0.0
"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)","DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",0.0
"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))","DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",0.0
DRUGMATRIX: Cyclooxygenase COX enzyme inhibition (substrate: Arachidonic acid),DRUGMATRIX: Cyclooxygenase COX enzyme inhibition (substrate: Arachidonic acid),0.0
DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),0.0
DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),0.0
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),0.0
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),0.0
DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),0.0
DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),0.0
DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),0.0
"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)","DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",0.0
DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),0.0
"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)","DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",0.0
DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),0.0
DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),0.0
DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),0.0
DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),0.0
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),0.0
DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),0.0
DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),0.0
"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)","DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",0.0
"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)","DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",0.0
"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)","DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",0.0
DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),0.0
DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),0.0
"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))","DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",0.0
"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))","DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",0.0
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),0.0
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),0.0
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),0.0
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),0.0
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),0.0
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR13808),DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR13808),0.0
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),0.0
DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),0.0
DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),0.0
"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)","DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",0.0
DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),0.0
DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),0.0
"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)","DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",0.0
Diffuse intrinsic pontine glioma (JHH-DIPG) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Glo,Diffuse intrinsic pontine glioma (JHH-DIPG) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Glo,0.015071386503655467
Diffuse intrinsic pontine glioma (SU-DIPG-XIII) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Glo,Diffuse intrinsic pontine glioma (SU-DIPG-XIII) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Glo,0.09317668386319782
Diffuse intrinsic pontine glioma (SU-DIPG-XVII) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Glo,Diffuse intrinsic pontine glioma (SU-DIPG-XVII) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Glo,0.013269638292474215
Diffuse intrinsic pontine glioma (SU-DIPG-XXV) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Fluor,Diffuse intrinsic pontine glioma (SU-DIPG-XXV) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Fluor,0.021892674509193202
Diffuse intrinsic pontine glioma (SU-DIPG-XXV) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Glo,Diffuse intrinsic pontine glioma (SU-DIPG-XXV) cell line screen of MIPE5.0 library: viability qHTS assay using CellTiter-Glo,-0.0
"FDA HLAED, alkaline phosphatase increase","FDA HLAED, alkaline phosphatase increase",0.5101956836655842
"FDA HLAED, gamma-glutamyl transferase (GGT) increase","FDA HLAED, gamma-glutamyl transferase (GGT) increase",0.1333745272916561
"FDA HLAED, lactate dehydrogenase (LDH) increase","FDA HLAED, lactate dehydrogenase (LDH) increase",0.016281789438231515
"FDA HLAED, liver enzyme composite activity","FDA HLAED, liver enzyme composite activity",0.7202573196123638
"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase","FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",1.0
"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase","FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",0.9198736042093513
Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,0.0
Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,0.0
Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,0.0
Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,0.0
Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,0.0
Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,0.0
Primary Screen for Target Class Profiling of Small Molecule Inhibitors of Methyltransferases,Primary Screen for Target Class Profiling of Small Molecule Inhibitors of Methyltransferases,0.10449985163753683
qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary,qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary,0.025469375533830732
CCRIS carcinogenicity studies,CCRIS carcinogenicity studies,0.06853924184137666
GENE-TOX mutagenicity studies,GENE-TOX mutagenicity studies,0.32603247324627954
Agonist activity at human OPRM1 in an in vitro assay with cellular components measured by scintillation proximity assay,Agonist activity at human OPRM1 in an in vitro assay with cellular components measured by scintillation proximity assay,0.0
Agonist activity at human PGR in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,Agonist activity at human PGR in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,0.0
Antagonist activity at human PGR in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,Antagonist activity at human PGR in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,0.0
Binding affinity towards human NR1I2 in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,Binding affinity towards human NR1I2 in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,0.0
Human mu receptor (Opioid receptors),Human mu receptor (Opioid receptors),0.0
Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex,0.0
"Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)","Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)",0.0
"Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)","Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)",0.0
Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,0.0
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr,Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr,0.0
Confirmatory Screen for Target Class Profiling of Small Molecule Inhibitors of Methyltransferases,Confirmatory Screen for Target Class Profiling of Small Molecule Inhibitors of Methyltransferases,-0.0
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,0.0
"DNDI: Chagas in Vitro, 96 hour","DNDI: Chagas in Vitro, 96 hour",0.0
"DNDI: HAT in Vitro, 72 hour","DNDI: HAT in Vitro, 72 hour",0.0
"DNDI: Malaria in Vitro, 72 hour","DNDI: Malaria in Vitro, 72 hour",0.0
"DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: ""Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.""","DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: ""Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.""",0.0
Diffuse intrinsic pontine glioma (JHH-DIPG) cell line screen of MIPE4.0 library: viability qHTS assay using CellTiter-Glo,Diffuse intrinsic pontine glioma (JHH-DIPG) cell line screen of MIPE4.0 library: viability qHTS assay using CellTiter-Glo,0.015709384621591035
Diffuse intrinsic pontine glioma (SU-DIPG-IV) cell line screen of MIPE4.0 library: viability qHTS assay using CellTiter-Glo,Diffuse intrinsic pontine glioma (SU-DIPG-IV) cell line screen of MIPE4.0 library: viability qHTS assay using CellTiter-Glo,0.10007150117630573
Diffuse intrinsic pontine glioma (SU-DIPG-VI) cell line screen of MIPE4.0 library: viability qHTS assay using CellTiter-Glo,Diffuse intrinsic pontine glioma (SU-DIPG-VI) cell line screen of MIPE4.0 library: viability qHTS assay using CellTiter-Glo,0.07006109758602994
Diffuse intrinsic pontine glioma (SU-DIPG-XIII) cell line screen of MIPE4.0 library: viability qHTS assay using CellTiter-Glo,Diffuse intrinsic pontine glioma (SU-DIPG-XIII) cell line screen of MIPE4.0 library: viability qHTS assay using CellTiter-Glo,0.4469949507864143
HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,0.029439443963910815
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,0.5249807154311068
High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,0.12362067299590909
Inhibition of CYP3A4,Inhibition of CYP3A4,-0.0
Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-taurocholate by topcount based membrane vesicle transport assay,Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-taurocholate by topcount based membrane vesicle transport assay,0.0
Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay,Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay,0.0
Inhibition of human ERG,Inhibition of human ERG,0.0
Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol7beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay,Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol7beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay,0.0
Inhibitor identification of human QSOX1 enzyme: high-throughput screening using HyperBlu(TM) assay,Inhibitor identification of human QSOX1 enzyme: high-throughput screening using HyperBlu(TM) assay,0.012543852157007597
Inhibitor identification of human QSOX1 enzyme: high-throughput screening using ROS-Glo(TM) assay,Inhibitor identification of human QSOX1 enzyme: high-throughput screening using ROS-Glo(TM) assay,0.01063457658513567
Inhibitory concentration against IKr potassium channel,Inhibitory concentration against IKr potassium channel,0.0
Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,0.0
NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) - Blood-Brain Barrier (BBB) Permeability Screen,NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) - Blood-Brain Barrier (BBB) Permeability Screen,0.016382850483207114
NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,0.07845879861746301
Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay,Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay,0.30949441911544995
"No assay is provided from Article 10.1002/med.21724: ""The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.""","No assay is provided from Article 10.1002/med.21724: ""The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.""",0.013157622087099658
Phospholipidosis-positive literature compound observed in rat,Phospholipidosis-positive literature compound observed in rat,0.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  AMO1_DSMZ cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  AMO1_DSMZ cell viability assay,0.022016341983053127
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  ARD_JJKsccE7 cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  ARD_JJKsccE7 cell viability assay,0.14936202528868509
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  ARP1_JJKsccF8 cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  ARP1_JJKsccF8 cell viability assay,0.07204844900257008
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  Delta47_JCRB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  Delta47_JCRB cell viability assay,0.10990038172611889
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  EJM_DSMZ cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  EJM_DSMZ cell viability assay,0.1719851122596269
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  FR4_PLB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  FR4_PLB cell viability assay,-0.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  H1112_PLB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  H1112_PLB cell viability assay,0.18146055539373687
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  INA6_PLB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  INA6_PLB cell viability assay,-0.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  JIM1_ECACC cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  JIM1_ECACC cell viability assay,-0.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  JIM3_ECACC cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  JIM3_ECACC cell viability assay,0.0546789013309077
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  JJN3_DSMZ cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  JJN3_DSMZ cell viability assay,0.007631154308751665
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  Karpas25_ECACC cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection:  Karpas25_ECACC cell viability assay,0.1740514827857045
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KHM11_PLB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KHM11_PLB cell viability assay,0.008435829532175039
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMM1_JCRB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMM1_JCRB cell viability assay,0.04011631412461271
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS12BM_JCRB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS12BM_JCRB cell viability assay,0.055031813517041867
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS12PE_JCRB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS12PE_JCRB cell viability assay,-0.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS20_JCRB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS20_JCRB cell viability assay,-0.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS21BM_JCRB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS21BM_JCRB cell viability assay,-0.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS26_JCRB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS26_JCRB cell viability assay,0.03147400489257472
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS27_JCRB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS27_JCRB cell viability assay,0.06433646502787721
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS28PE_JCRB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS28PE_JCRB cell viability assay,-0.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS34_JCRB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: KMS34_JCRB cell viability assay,0.021533765740102594
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: Karpas417_ECACC cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: Karpas417_ECACC cell viability assay,0.033741239590530624
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: Karpas620_DSMZ cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: Karpas620_DSMZ cell viability assay,0.04300604290586485
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: L363_DSMZ cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: L363_DSMZ cell viability assay,0.04313519027409991
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: LP1_DSMZ cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: LP1_DSMZ cell viability assay,0.05996965271877332
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: MM1R_ATCC cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: MM1R_ATCC cell viability assay,0.04832040796760709
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: MM1S_ATCC cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: MM1S_ATCC cell viability assay,-0.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: MMM1_PLB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: MMM1_PLB cell viability assay,-0.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: MOLP8_DSMZ cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: MOLP8_DSMZ cell viability assay,0.0713102804521754
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: NCIH929_DSMZ cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: NCIH929_DSMZ cell viability assay,0.02338743086200494
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: OCIMY1_PLB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: OCIMY1_PLB cell viability assay,-0.0
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: OCIMY5_PLB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: OCIMY5_PLB cell viability assay,0.008895885725804043
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: OCIMY7_PLB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: OCIMY7_PLB cell viability assay,0.00864738407978253
Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: OPM1_PLB cell viability assay,Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against the NCATS MIPE library collection: OPM1_PLB cell viability assay,0.04948377936125934
Rescue cell viability in cybrid cells with a genetic mutation in complex 1 of the mitochondria,Rescue cell viability in cybrid cells with a genetic mutation in complex 1 of the mitochondria,0.3230339917441932
Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,0.07011605724898477
qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),0.10792577861660202
qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),0.12333957077813203
qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),0.02326977563053623
qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),0.048315094977802744
qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,-0.0
qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,0.012752345902516794
qHTS for Inhibitors of ATXN expression: Validation,qHTS for Inhibitors of ATXN expression: Validation,0.10652952070342275
qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,0.11780613362504135
qHTS for inhibitors of binding or entry into cells for Marburg Virus,qHTS for inhibitors of binding or entry into cells for Marburg Virus,0.2595616723115327
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells),qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells),-0.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT2 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT2 cells,-0.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells,0.005810728402661958
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells,0.03435529375560286
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells,0.006604822796978709
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells,-0.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells,0.046825738729426025
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells,0.006548730937939323
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells,0.038611299915646644
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells,-0.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells,0.030999362740951865
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells,0.03837218281388485
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells,0.03680732605771372
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells,0.05096089337761744
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells,0.006805172073317415
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells,0.08167087194934632
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells,0.015564198806631895
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells,-0.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells,0.02444251986607706
96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,0.07832246199700753
Aqueous Solubility from MLSMR Stock Solutions,Aqueous Solubility from MLSMR Stock Solutions,0.09551688243598316
BK Channel Variant Modulator Selectivity Assay,BK Channel Variant Modulator Selectivity Assay,0.03784424629656282
Cell Viability - H-4-II-E,Cell Viability - H-4-II-E,0.018796635478545817
Cell Viability - Hek293,Cell Viability - Hek293,0.011741918273120707
Cell Viability - Jurkat,Cell Viability - Jurkat,0.03585623313755619
Cell Viability - LYMP1-002 - Assay at 40 hr,Cell Viability - LYMP1-002 - Assay at 40 hr,0.06268095850497718
Cell Viability - LYMP1-003 - Assay at 40 hr,Cell Viability - LYMP1-003 - Assay at 40 hr,0.05939481171690297
Cell Viability - LYMP2-010,Cell Viability - LYMP2-010,0.023164927744372864
Cell Viability - LYMP2-018,Cell Viability - LYMP2-018,0.06578017191240684
Cell Viability - LYMP2-022,Cell Viability - LYMP2-022,0.011812378282689065
Cell Viability - LYMP2-024,Cell Viability - LYMP2-024,0.026875668089283027
Cell Viability - N2a,Cell Viability - N2a,0.011103618368594735
Cell Viability - NIH 3T3,Cell Viability - NIH 3T3,0.007874685352721903
Cell Viability - Renal Proximal Tubule,Cell Viability - Renal Proximal Tubule,0.05772233796714831
Cell Viability - SH-SY5Y,Cell Viability - SH-SY5Y,0.0435955757379358
Cell Viability - SK-N-SH,Cell Viability - SK-N-SH,0.09100166698314618
Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,0.055007825732989186
Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells),Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells),-0.0
Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7K cells),Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7K cells),-0.0
HTS to identify compounds that affect the blood-brain barrier permeability in vitro,HTS to identify compounds that affect the blood-brain barrier permeability in vitro,0.0957791912399415
High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,0.017013100249115502
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),0.06908172059504425
Human A549 Lung Tumor Cell Growth Inhibition Assay,Human A549 Lung Tumor Cell Growth Inhibition Assay,0.021619766164095455
Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,0.01216194375605103
Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,0.027753354016115853
Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,0.02701476767049758
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,0.020620054060499996
Leishmania major promastigote HTS,Leishmania major promastigote HTS,-0.0
Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,0.10388951047986293
MDR,MDR,0.04713692575202423
MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,0.1401380910435972
MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,0.1850577764715147
MLPCN Streptokinase Expression Inhibition,MLPCN Streptokinase Expression Inhibition,0.5938820007040714
MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,0.05657304276537766
MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,0.15278763796892272
"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype","Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",-0.0
NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,-0.0
NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,0.07093626108161034
Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay,Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay,0.016938770400591604
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,-0.0
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,-0.0
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,0.03412242831744733
"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation","Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",0.027798779290976783
"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation","Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",0.010408944730082397
qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,0.048915838901302154
qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,0.008273241897708348
qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,-0.0
qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,0.0
"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel","qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",-0.0
"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel","qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",0.03619537048324441
qHTS Assay for Inhibitors of N-terminal methyltransferase 1 (NTMT1): LOPAC validation of the NTMT1 SAHH-coupled ThioGlo3 Assay,qHTS Assay for Inhibitors of N-terminal methyltransferase 1 (NTMT1): LOPAC validation of the NTMT1 SAHH-coupled ThioGlo3 Assay,0.0398063128366495
qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,0.03110523511295833
qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,0.07053025594925887
qHTS assay for small molecule activators of the p53 signaling pathway,qHTS assay for small molecule activators of the p53 signaling pathway,-0.0
qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,-0.0
qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,-0.0
qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,0.01812190593414896
qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,0.010384758949199218
qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,0.04291107257341041
qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway ,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway ,0.01112782629076782
qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),-0.0
qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,-0.0
qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,0.01695559119808193
qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,-0.0
qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,0.018863411199747965
qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,0.022133021406484384
qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,0.0267770632626762
qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,0.02853052284720229
qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,0.04365371981379667
Counterscreen for BLMA Inhibitors: ADP Fluorescence Polarization Displacement Assay,Counterscreen for BLMA Inhibitors: ADP Fluorescence Polarization Displacement Assay,-0.0
Counterscreen for RECQ1 Inhibitors: ADP Fluorescence Polarization Displacement Assay,Counterscreen for RECQ1 Inhibitors: ADP Fluorescence Polarization Displacement Assay,-0.0
Agonist activity at rat Ar in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,Agonist activity at rat Ar in an in vitro cell free assay measured by time-resolved fluorescence resonance energy transfer method,0.0
Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N oxygen probe based fluorescence assay,Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N oxygen probe based fluorescence assay,0.0
Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,-0.0
Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,-0.0
Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,0.04084499407246076
Nrf2 qHTS screen for inhibitors: Nrf2 A549 ARE-Fluc Confirmation Assay for Hit Validation,Nrf2 qHTS screen for inhibitors: Nrf2 A549 ARE-Fluc Confirmation Assay for Hit Validation,0.0
Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,-0.0
Total Cmax in human administered as single dose,Total Cmax in human administered as single dose,0.0
Unbound Cmax in human plasma,Unbound Cmax in human plasma,0.0
Wombat Data for BeliefDocking,Wombat Data for BeliefDocking,0.0
384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors,384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors,0.00467615760493951
384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors,384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors,-0.0
DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,0.03964852011927761
DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,-0.0
DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,0.03839240279091259
DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,0.1264439262061249
DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,0.0848531254523198
Furin counterscreen qHTS for Zika virus inhibitors,Furin counterscreen qHTS for Zika virus inhibitors,0.04084464996284258
NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,0.007986485904107943
NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,0.02573871286374178
NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,0.013109012762377291
NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,0.013571312251593403
NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,0.030558892112071058
NCI human tumor cell line growth inhibition assay. Data for the CAKI Renal cell line,NCI human tumor cell line growth inhibition assay. Data for the CAKI Renal cell line,0.012062193768630191
NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,0.012589094643430096
NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the DU45 Prostate cell line,NCI human tumor cell line growth inhibition assay. Data for the DU45 Prostate cell line,0.07065822326471206
NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,0.016797227536015362
NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the HCT16 Colon cell line,NCI human tumor cell line growth inhibition assay. Data for the HCT16 Colon cell line,0.012789207925233463
NCI human tumor cell line growth inhibition assay. Data for the HCT5 Colon cell line,NCI human tumor cell line growth inhibition assay. Data for the HCT5 Colon cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,0.012918856204817288
NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,0.0514454510417194
NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,0.013050400336405199
NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,0.013720125443844971
NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,0.01615244320823279
NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,0.011949253236822424
NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,0.06903167544244089
NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,0.026293478117171552
NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,0.02906908551124222
NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,0.043379703932681854
NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,0.013098540848993475
NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,0.01513860116117877
NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,0.012874880807934521
NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,0.01300678530566465
NCI human tumor cell line growth inhibition assay. Data for the SNB9 Central Nervous System cell line,NCI human tumor cell line growth inhibition assay. Data for the SNB9 Central Nervous System cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,-0.0
NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,0.013213768854855118
NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,0.015129194637989294
NCI human tumor cell line growth inhibition assay. Data for the TK0 Renal cell line,NCI human tumor cell line growth inhibition assay. Data for the TK0 Renal cell line,0.03796022206070685
NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,0.013164245602054873
NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,0.0378059525781802
NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,0.027673500131103326
NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,-0.0
Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors,Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors,0.03994768453116146
Confirmatory qHTS to identify inhibitors of SARS-CoV-2 cell entry,Confirmatory qHTS to identify inhibitors of SARS-CoV-2 cell entry,-0.0
Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB,Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB,0.0
Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,0.0
VSVG counterscreen qHTS to identify inhibitors of SARS-CoV-2 cell entry,VSVG counterscreen qHTS to identify inhibitors of SARS-CoV-2 cell entry,-0.0
A counter screen for small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,A counter screen for small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,-0.0
A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhi identified in the primary screen,A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhi identified in the primary screen,-0.0
A screen for inhibitors of the PhoP regulon in Salmonella Typhi using a modified counterscreen,A screen for inhibitors of the PhoP regulon in Salmonella Typhi using a modified counterscreen,-0.0
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,0.0
Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,0.013150968645151407
Cell Viability Profiling of Human Lymphoblast Cell Lines,Cell Viability Profiling of Human Lymphoblast Cell Lines,0.006077658069807673
Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors,Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors,-0.0
Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors,Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors,0.050166557344771115
Cytotoxicity activity against human HepG2 cells assessed by CellTiter-Glo luminescent cell viability assay.,Cytotoxicity activity against human HepG2 cells assessed by CellTiter-Glo luminescent cell viability assay.,-0.0
Decreased HeLa cell count-IC50,Decreased HeLa cell count-IC50,0.007232624844093592
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells,HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells,0.0
Increased HeLa cells with 2N DNA content-IC50,Increased HeLa cells with 2N DNA content-IC50,0.007849080374029283
Ligands of bioamine (Class A) GPCRs,Ligands of bioamine (Class A) GPCRs,0.0
Luminescence Microorganism-Based Dose Confirmation HTS to Identify Compounds Cytotoxic to SK(-)GAS Group A Streptococcus,Luminescence Microorganism-Based Dose Confirmation HTS to Identify Compounds Cytotoxic to SK(-)GAS Group A Streptococcus,0.0
Luminescence Microorganism-Based Dose Confirmation HTS to Identify Inhibitors of Streptokinase Promotor Activity,Luminescence Microorganism-Based Dose Confirmation HTS to Identify Inhibitors of Streptokinase Promotor Activity,0.0
Luminescence Microorganism-Based Dose Response HTS to Identify Compounds Cytotoxic to Streptococcus,Luminescence Microorganism-Based Dose Response HTS to Identify Compounds Cytotoxic to Streptococcus,-0.0
Luminescence cell-based Retest at Dose assay to determine EWS/Fli1 dependent TC71 mammalian cell cytotoxity  Measured in Cell-Based System Using Plate Reader - 7014-04_Inhibitor_Dose_CherryPick_Activity,Luminescence cell-based Retest at Dose assay to determine EWS/Fli1 dependent TC71 mammalian cell cytotoxity  Measured in Cell-Based System Using Plate Reader - 7014-04_Inhibitor_Dose_CherryPick_Activity,0.0
NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in B6D2F1 (BDF1) mice,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in B6D2F1 (BDF1) mice,0.00462028825940142
NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,0.022307145015711495
SANGER: Inhibition of human 697 cell growth in a cell viability assay.,SANGER: Inhibition of human 697 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human 8-MG-BA cell growth in a cell viability assay.,SANGER: Inhibition of human 8-MG-BA cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human A101D cell growth in a cell viability assay.,SANGER: Inhibition of human A101D cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human A253 cell growth in a cell viability assay.,SANGER: Inhibition of human A253 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human A3-KAW cell growth in a cell viability assay.,SANGER: Inhibition of human A3-KAW cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human A388 cell growth in a cell viability assay.,SANGER: Inhibition of human A388 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human A4-Fuk cell growth in a cell viability assay.,SANGER: Inhibition of human A4-Fuk cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human A498 cell growth in a cell viability assay.,SANGER: Inhibition of human A498 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ACN cell growth in a cell viability assay.,SANGER: Inhibition of human ACN cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ALL-PO cell growth in a cell viability assay.,SANGER: Inhibition of human ALL-PO cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human AM-38 cell growth in a cell viability assay.,SANGER: Inhibition of human AM-38 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ARH-77 cell growth in a cell viability assay.,SANGER: Inhibition of human ARH-77 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ATN cell growth in a cell viability assay.,SANGER: Inhibition of human ATN cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BB30-HNC cell growth in a cell viability assay.,SANGER: Inhibition of human BB30-HNC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BB49-HNC cell growth in a cell viability assay.,SANGER: Inhibition of human BB49-HNC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BB65-RCC cell growth in a cell viability assay.,SANGER: Inhibition of human BB65-RCC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BC cell growth in a cell viability assay.,SANGER: Inhibition of human BC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BE3 cell growth in a cell viability assay.,SANGER: Inhibition of human BE3 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BL-41 cell growth in a cell viability assay.,SANGER: Inhibition of human BL-41 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BL-70 cell growth in a cell viability assay.,SANGER: Inhibition of human BL-70 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BT-474 cell growth in a cell viability assay.,SANGER: Inhibition of human BT-474 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BV73 cell growth in a cell viability assay.,SANGER: Inhibition of human BV73 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human Becker cell growth in a cell viability assay.,SANGER: Inhibition of human Becker cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human C2BBe1 cell growth in a cell viability assay.,SANGER: Inhibition of human C2BBe1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human C8166 cell growth in a cell viability assay.,SANGER: Inhibition of human C8166 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CAS cell growth in a cell viability assay.,SANGER: Inhibition of human CAS cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CCRF-CEM cell growth in a cell viability assay.,SANGER: Inhibition of human CCRF-CEM cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CESS cell growth in a cell viability assay.,SANGER: Inhibition of human CESS cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CGTH-W cell growth in a cell viability assay.,SANGER: Inhibition of human CGTH-W cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CMK cell growth in a cell viability assay.,SANGER: Inhibition of human CMK cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human COLO-320-HSR cell growth in a cell viability assay.,SANGER: Inhibition of human COLO-320-HSR cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human COLO-668 cell growth in a cell viability assay.,SANGER: Inhibition of human COLO-668 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human COLO-684 cell growth in a cell viability assay.,SANGER: Inhibition of human COLO-684 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human COLO-800 cell growth in a cell viability assay.,SANGER: Inhibition of human COLO-800 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human COLO-829 cell growth in a cell viability assay.,SANGER: Inhibition of human COLO-829 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human COR-L279 cell growth in a cell viability assay.,SANGER: Inhibition of human COR-L279 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CP66-MEL cell growth in a cell viability assay.,SANGER: Inhibition of human CP66-MEL cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CTB cell growth in a cell viability assay.,SANGER: Inhibition of human CTB cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CTV cell growth in a cell viability assay.,SANGER: Inhibition of human CTV cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human Calu-6 cell growth in a cell viability assay.,SANGER: Inhibition of human Calu-6 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human D-247MG cell growth in a cell viability assay.,SANGER: Inhibition of human D-247MG cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human D-263MG cell growth in a cell viability assay.,SANGER: Inhibition of human D-263MG cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human D-283MED cell growth in a cell viability assay.,SANGER: Inhibition of human D-283MED cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human D-392MG cell growth in a cell viability assay.,SANGER: Inhibition of human D-392MG cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human D-502MG cell growth in a cell viability assay.,SANGER: Inhibition of human D-502MG cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human DB cell growth in a cell viability assay.,SANGER: Inhibition of human DB cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human DEL cell growth in a cell viability assay.,SANGER: Inhibition of human DEL cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human DJM cell growth in a cell viability assay.,SANGER: Inhibition of human DJM cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human DMS14 cell growth in a cell viability assay.,SANGER: Inhibition of human DMS14 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human DMS-79 cell growth in a cell viability assay.,SANGER: Inhibition of human DMS-79 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human DOHH-2 cell growth in a cell viability assay.,SANGER: Inhibition of human DOHH-2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human DSH1 cell growth in a cell viability assay.,SANGER: Inhibition of human DSH1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human DU-4475 cell growth in a cell viability assay.,SANGER: Inhibition of human DU-4475 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human Daudi cell growth in a cell viability assay.,SANGER: Inhibition of human Daudi cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human EKVX cell growth in a cell viability assay.,SANGER: Inhibition of human EKVX cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human EM-2 cell growth in a cell viability assay.,SANGER: Inhibition of human EM-2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ES1 cell growth in a cell viability assay.,SANGER: Inhibition of human ES1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ES3 cell growth in a cell viability assay.,SANGER: Inhibition of human ES3 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ES4 cell growth in a cell viability assay.,SANGER: Inhibition of human ES4 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ES5 cell growth in a cell viability assay.,SANGER: Inhibition of human ES5 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ES6 cell growth in a cell viability assay.,SANGER: Inhibition of human ES6 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ES7 cell growth in a cell viability assay.,SANGER: Inhibition of human ES7 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ES8 cell growth in a cell viability assay.,SANGER: Inhibition of human ES8 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ETK cell growth in a cell viability assay.,SANGER: Inhibition of human ETK cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human EW cell growth in a cell viability assay.,SANGER: Inhibition of human EW cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human EW1 cell growth in a cell viability assay.,SANGER: Inhibition of human EW1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human EW3 cell growth in a cell viability assay.,SANGER: Inhibition of human EW3 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human EW6 cell growth in a cell viability assay.,SANGER: Inhibition of human EW6 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human EW8 cell growth in a cell viability assay.,SANGER: Inhibition of human EW8 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human EW-24 cell growth in a cell viability assay.,SANGER: Inhibition of human EW-24 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human EW-3 cell growth in a cell viability assay.,SANGER: Inhibition of human EW-3 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human EoL-cell cell growth in a cell viability assay.,SANGER: Inhibition of human EoL-cell cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human GAK cell growth in a cell viability assay.,SANGER: Inhibition of human GAK cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human GB cell growth in a cell viability assay.,SANGER: Inhibition of human GB cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human GCIY cell growth in a cell viability assay.,SANGER: Inhibition of human GCIY cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human GDM cell growth in a cell viability assay.,SANGER: Inhibition of human GDM cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human GI cell growth in a cell viability assay.,SANGER: Inhibition of human GI cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human GI-ME-N cell growth in a cell viability assay.,SANGER: Inhibition of human GI-ME-N cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human GOTO cell growth in a cell viability assay.,SANGER: Inhibition of human GOTO cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human GR-ST cell growth in a cell viability assay.,SANGER: Inhibition of human GR-ST cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human GT3TKB cell growth in a cell viability assay.,SANGER: Inhibition of human GT3TKB cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HAL-01 cell growth in a cell viability assay.,SANGER: Inhibition of human HAL-01 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HC cell growth in a cell viability assay.,SANGER: Inhibition of human HC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HCC2218 cell growth in a cell viability assay.,SANGER: Inhibition of human HCC2218 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HCC2998 cell growth in a cell viability assay.,SANGER: Inhibition of human HCC2998 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HCE-T cell growth in a cell viability assay.,SANGER: Inhibition of human HCE-T cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HD-MY-Z cell growth in a cell viability assay.,SANGER: Inhibition of human HD-MY-Z cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HDLM-2 cell growth in a cell viability assay.,SANGER: Inhibition of human HDLM-2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HEL cell growth in a cell viability assay.,SANGER: Inhibition of human HEL cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HH cell growth in a cell viability assay.,SANGER: Inhibition of human HH cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HL-60 cell growth in a cell viability assay.,SANGER: Inhibition of human HL-60 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HOP-62 cell growth in a cell viability assay.,SANGER: Inhibition of human HOP-62 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HT cell growth in a cell viability assay.,SANGER: Inhibition of human HT cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HT44 cell growth in a cell viability assay.,SANGER: Inhibition of human HT44 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HUTU-80 cell growth in a cell viability assay.,SANGER: Inhibition of human HUTU-80 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human IST-MEL1 cell growth in a cell viability assay.,SANGER: Inhibition of human IST-MEL1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human IST-MES1 cell growth in a cell viability assay.,SANGER: Inhibition of human IST-MES1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human IST-SL1 cell growth in a cell viability assay.,SANGER: Inhibition of human IST-SL1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human IST-SL2 cell growth in a cell viability assay.,SANGER: Inhibition of human IST-SL2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay.,SANGER: Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human JAR cell growth in a cell viability assay.,SANGER: Inhibition of human JAR cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human JVM-2 cell growth in a cell viability assay.,SANGER: Inhibition of human JVM-2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human JVM-3 cell growth in a cell viability assay.,SANGER: Inhibition of human JVM-3 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human K-562 cell growth in a cell viability assay.,SANGER: Inhibition of human K-562 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human K5 cell growth in a cell viability assay.,SANGER: Inhibition of human K5 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KALS cell growth in a cell viability assay.,SANGER: Inhibition of human KALS cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KARPAS-299 cell growth in a cell viability assay.,SANGER: Inhibition of human KARPAS-299 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KARPAS-422 cell growth in a cell viability assay.,SANGER: Inhibition of human KARPAS-422 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KARPAS-45 cell growth in a cell viability assay.,SANGER: Inhibition of human KARPAS-45 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KASUMI cell growth in a cell viability assay.,SANGER: Inhibition of human KASUMI cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KE-37 cell growth in a cell viability assay.,SANGER: Inhibition of human KE-37 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KG cell growth in a cell viability assay.,SANGER: Inhibition of human KG cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KGN cell growth in a cell viability assay.,SANGER: Inhibition of human KGN cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KINGS cell growth in a cell viability assay.,SANGER: Inhibition of human KINGS cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KM-H2 cell growth in a cell viability assay.,SANGER: Inhibition of human KM-H2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KM12 cell growth in a cell viability assay.,SANGER: Inhibition of human KM12 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KMOE-2 cell growth in a cell viability assay.,SANGER: Inhibition of human KMOE-2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KNS-42 cell growth in a cell viability assay.,SANGER: Inhibition of human KNS-42 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KNS-81-FD cell growth in a cell viability assay.,SANGER: Inhibition of human KNS-81-FD cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KP-N-YS cell growth in a cell viability assay.,SANGER: Inhibition of human KP-N-YS cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KS cell growth in a cell viability assay.,SANGER: Inhibition of human KS cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KU812 cell growth in a cell viability assay.,SANGER: Inhibition of human KU812 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KURAMOCHI cell growth in a cell viability assay.,SANGER: Inhibition of human KURAMOCHI cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KY821 cell growth in a cell viability assay.,SANGER: Inhibition of human KY821 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human L-363 cell growth in a cell viability assay.,SANGER: Inhibition of human L-363 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human L-428 cell growth in a cell viability assay.,SANGER: Inhibition of human L-428 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LAMA-84 cell growth in a cell viability assay.,SANGER: Inhibition of human LAMA-84 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LAN-6 cell growth in a cell viability assay.,SANGER: Inhibition of human LAN-6 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LB1047-RCC cell growth in a cell viability assay.,SANGER: Inhibition of human LB1047-RCC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LB2241-RCC cell growth in a cell viability assay.,SANGER: Inhibition of human LB2241-RCC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LB2518-MEL cell growth in a cell viability assay.,SANGER: Inhibition of human LB2518-MEL cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LB373-MEL-D cell growth in a cell viability assay.,SANGER: Inhibition of human LB373-MEL-D cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LB771-HNC cell growth in a cell viability assay.,SANGER: Inhibition of human LB771-HNC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LB831-BLC cell growth in a cell viability assay.,SANGER: Inhibition of human LB831-BLC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LB996-RCC cell growth in a cell viability assay.,SANGER: Inhibition of human LB996-RCC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LC-2-ad cell growth in a cell viability assay.,SANGER: Inhibition of human LC-2-ad cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay.,SANGER: Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LOXIMVI cell growth in a cell viability assay.,SANGER: Inhibition of human LOXIMVI cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LS034 cell growth in a cell viability assay.,SANGER: Inhibition of human LS034 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LS23 cell growth in a cell viability assay.,SANGER: Inhibition of human LS23 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LS-411N cell growth in a cell viability assay.,SANGER: Inhibition of human LS-411N cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LS-513 cell growth in a cell viability assay.,SANGER: Inhibition of human LS-513 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LU34-A cell growth in a cell viability assay.,SANGER: Inhibition of human LU34-A cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LU39 cell growth in a cell viability assay.,SANGER: Inhibition of human LU39 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LU-65 cell growth in a cell viability assay.,SANGER: Inhibition of human LU-65 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LXF-289 cell growth in a cell viability assay.,SANGER: Inhibition of human LXF-289 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MC116 cell growth in a cell viability assay.,SANGER: Inhibition of human MC116 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MEG-01 cell growth in a cell viability assay.,SANGER: Inhibition of human MEG-01 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MFH-ino cell growth in a cell viability assay.,SANGER: Inhibition of human MFH-ino cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MHH-NB1 cell growth in a cell viability assay.,SANGER: Inhibition of human MHH-NB1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MHH-PREB cell growth in a cell viability assay.,SANGER: Inhibition of human MHH-PREB cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ML-2 cell growth in a cell viability assay.,SANGER: Inhibition of human ML-2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MLMA cell growth in a cell viability assay.,SANGER: Inhibition of human MLMA cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MMAC-SF cell growth in a cell viability assay.,SANGER: Inhibition of human MMAC-SF cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MN-60 cell growth in a cell viability assay.,SANGER: Inhibition of human MN-60 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MOLT6 cell growth in a cell viability assay.,SANGER: Inhibition of human MOLT6 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MOLT-4 cell growth in a cell viability assay.,SANGER: Inhibition of human MOLT-4 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MONO-MAC-6 cell growth in a cell viability assay.,SANGER: Inhibition of human MONO-MAC-6 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MPP-89 cell growth in a cell viability assay.,SANGER: Inhibition of human MPP-89 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MS cell growth in a cell viability assay.,SANGER: Inhibition of human MS cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MSTO-211H cell growth in a cell viability assay.,SANGER: Inhibition of human MSTO-211H cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MV-41 cell growth in a cell viability assay.,SANGER: Inhibition of human MV-41 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MZ1-PC cell growth in a cell viability assay.,SANGER: Inhibition of human MZ1-PC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MZ2-MEL cell growth in a cell viability assay.,SANGER: Inhibition of human MZ2-MEL cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MZ7-mel cell growth in a cell viability assay.,SANGER: Inhibition of human MZ7-mel cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NALM-6 cell growth in a cell viability assay.,SANGER: Inhibition of human NALM-6 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NB1 cell growth in a cell viability assay.,SANGER: Inhibition of human NB1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NB10 cell growth in a cell viability assay.,SANGER: Inhibition of human NB10 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NB12 cell growth in a cell viability assay.,SANGER: Inhibition of human NB12 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NB13 cell growth in a cell viability assay.,SANGER: Inhibition of human NB13 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NB14 cell growth in a cell viability assay.,SANGER: Inhibition of human NB14 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NB5 cell growth in a cell viability assay.,SANGER: Inhibition of human NB5 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NB6 cell growth in a cell viability assay.,SANGER: Inhibition of human NB6 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NB69 cell growth in a cell viability assay.,SANGER: Inhibition of human NB69 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCCIT cell growth in a cell viability assay.,SANGER: Inhibition of human NCCIT cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H1092 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H1092 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H1155 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H1155 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H1299 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H1299 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H1304 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H1304 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H1355 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H1355 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H1581 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H1581 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H1648 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H1648 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H1650 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H1650 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H1770 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H1770 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H1838 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H1838 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H209 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H209 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H2126 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H2126 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H226 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H226 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H23 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H23 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H446 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H446 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H510A cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H510A cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H526 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H526 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H69 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H69 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H747 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H747 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H82 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H82 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-SNU cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-SNU cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-SNU-5 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-SNU-5 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NEC8 cell growth in a cell viability assay.,SANGER: Inhibition of human NEC8 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NH2 cell growth in a cell viability assay.,SANGER: Inhibition of human NH2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NKM cell growth in a cell viability assay.,SANGER: Inhibition of human NKM cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NMC-G1 cell growth in a cell viability assay.,SANGER: Inhibition of human NMC-G1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NOMO cell growth in a cell viability assay.,SANGER: Inhibition of human NOMO cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NOS cell growth in a cell viability assay.,SANGER: Inhibition of human NOS cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay.,SANGER: Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human OCI-AML2 cell growth in a cell viability assay.,SANGER: Inhibition of human OCI-AML2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human OCUB-M cell growth in a cell viability assay.,SANGER: Inhibition of human OCUB-M cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human OMC cell growth in a cell viability assay.,SANGER: Inhibition of human OMC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ONS-76 cell growth in a cell viability assay.,SANGER: Inhibition of human ONS-76 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human OS-RC-2 cell growth in a cell viability assay.,SANGER: Inhibition of human OS-RC-2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human OVCAR-4 cell growth in a cell viability assay.,SANGER: Inhibition of human OVCAR-4 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human P30-OHK cell growth in a cell viability assay.,SANGER: Inhibition of human P30-OHK cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human PF-382 cell growth in a cell viability assay.,SANGER: Inhibition of human PF-382 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human PSN1 cell growth in a cell viability assay.,SANGER: Inhibition of human PSN1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human QIMR-WIL cell growth in a cell viability assay.,SANGER: Inhibition of human QIMR-WIL cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RCC10RGB cell growth in a cell viability assay.,SANGER: Inhibition of human RCC10RGB cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RH cell growth in a cell viability assay.,SANGER: Inhibition of human RH cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RKO cell growth in a cell viability assay.,SANGER: Inhibition of human RKO cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RPMI-6666 cell growth in a cell viability assay.,SANGER: Inhibition of human RPMI-6666 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RPMI-8226 cell growth in a cell viability assay.,SANGER: Inhibition of human RPMI-8226 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RPMI-8402 cell growth in a cell viability assay.,SANGER: Inhibition of human RPMI-8402 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RPMI-8866 cell growth in a cell viability assay.,SANGER: Inhibition of human RPMI-8866 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RS41 cell growth in a cell viability assay.,SANGER: Inhibition of human RS41 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RXF393 cell growth in a cell viability assay.,SANGER: Inhibition of human RXF393 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay.,SANGER: Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SBC cell growth in a cell viability assay.,SANGER: Inhibition of human SBC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SCC-3 cell growth in a cell viability assay.,SANGER: Inhibition of human SCC-3 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SF126 cell growth in a cell viability assay.,SANGER: Inhibition of human SF126 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SF268 cell growth in a cell viability assay.,SANGER: Inhibition of human SF268 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SF539 cell growth in a cell viability assay.,SANGER: Inhibition of human SF539 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SH-4 cell growth in a cell viability assay.,SANGER: Inhibition of human SH-4 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SHP-77 cell growth in a cell viability assay.,SANGER: Inhibition of human SHP-77 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SIG-M5 cell growth in a cell viability assay.,SANGER: Inhibition of human SIG-M5 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SJSA cell growth in a cell viability assay.,SANGER: Inhibition of human SJSA cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SK-LMS cell growth in a cell viability assay.,SANGER: Inhibition of human SK-LMS cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SK-MEL cell growth in a cell viability assay.,SANGER: Inhibition of human SK-MEL cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SK-MEL-2 cell growth in a cell viability assay.,SANGER: Inhibition of human SK-MEL-2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SK-N-DZ cell growth in a cell viability assay.,SANGER: Inhibition of human SK-N-DZ cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SK-NEP cell growth in a cell viability assay.,SANGER: Inhibition of human SK-NEP cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SK-PN-DW cell growth in a cell viability assay.,SANGER: Inhibition of human SK-PN-DW cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SK-UT cell growth in a cell viability assay.,SANGER: Inhibition of human SK-UT cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SNB75 cell growth in a cell viability assay.,SANGER: Inhibition of human SNB75 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SR cell growth in a cell viability assay.,SANGER: Inhibition of human SR cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ST486 cell growth in a cell viability assay.,SANGER: Inhibition of human ST486 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SU-DHL cell growth in a cell viability assay.,SANGER: Inhibition of human SU-DHL cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SW872 cell growth in a cell viability assay.,SANGER: Inhibition of human SW872 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SW954 cell growth in a cell viability assay.,SANGER: Inhibition of human SW954 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SW962 cell growth in a cell viability assay.,SANGER: Inhibition of human SW962 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human TE cell growth in a cell viability assay.,SANGER: Inhibition of human TE cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human TE0 cell growth in a cell viability assay.,SANGER: Inhibition of human TE0 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human TE2 cell growth in a cell viability assay.,SANGER: Inhibition of human TE2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human TE5 cell growth in a cell viability assay.,SANGER: Inhibition of human TE5 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human TE-5 cell growth in a cell viability assay.,SANGER: Inhibition of human TE-5 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human TE-6 cell growth in a cell viability assay.,SANGER: Inhibition of human TE-6 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human TE-8 cell growth in a cell viability assay.,SANGER: Inhibition of human TE-8 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human TE-9 cell growth in a cell viability assay.,SANGER: Inhibition of human TE-9 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human TGBC1TKB cell growth in a cell viability assay.,SANGER: Inhibition of human TGBC1TKB cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human TK10 cell growth in a cell viability assay.,SANGER: Inhibition of human TK10 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human U-266 cell growth in a cell viability assay.,SANGER: Inhibition of human U-266 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human U-87-MG cell growth in a cell viability assay.,SANGER: Inhibition of human U-87-MG cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human UACC-257 cell growth in a cell viability assay.,SANGER: Inhibition of human UACC-257 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human VA-ES-BJ cell growth in a cell viability assay.,SANGER: Inhibition of human VA-ES-BJ cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human no0 cell growth in a cell viability assay.,SANGER: Inhibition of human no0 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human no1 cell growth in a cell viability assay.,SANGER: Inhibition of human no1 cell growth in a cell viability assay.,0.0
Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,0.016671493308101564
alkaline phosphatase stimulation in WNT3A conditioned C2C12 cells-IC50,alkaline phosphatase stimulation in WNT3A conditioned C2C12 cells-IC50,0.004062132212875153
nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-IC50,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-IC50,-0.0
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells,qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells,-0.0
Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay,Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay,0.0046532533063710965
Binding affinity towards human HTR5A in an in vitro assay with cellular components measured by membrane filtration,Binding affinity towards human HTR5A in an in vitro assay with cellular components measured by membrane filtration,0.0
Binding affinity towards human HTR6 in an in vitro assay with cellular components measured by membrane filtration,Binding affinity towards human HTR6 in an in vitro assay with cellular components measured by membrane filtration,0.0
Binding affinity towards human HTR7 in an in vitro assay with cellular components measured by membrane filtration,Binding affinity towards human HTR7 in an in vitro assay with cellular components measured by membrane filtration,0.0
Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin,0.0
Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,0.0
Experimentally measured binding affinity data derived from PDB,Experimentally measured binding affinity data derived from PDB,0.0
NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon 26 Adenocarcinoma (intraperitoneal) in CD2F1 (CDF1) mice,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon 26 Adenocarcinoma (intraperitoneal) in CD2F1 (CDF1) mice,0.004848578326861811
NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,0.005183649645422024
Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol7beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay,Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol7beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay,0.0
Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,0.003989561304161938
Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,0.02565359731016756
Cell Proliferation Assay Versus the ED40515 IL2 Dependent  ATL cell lines,Cell Proliferation Assay Versus the ED40515 IL2 Dependent  ATL cell lines,0.014662105987644945
Cell Proliferation Assay Versus the ED40515 IL2 Independent  ATL cell lines,Cell Proliferation Assay Versus the ED40515 IL2 Independent  ATL cell lines,-0.0
"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (A278, Adherent)","Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (A278, Adherent)",-0.0
"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (SN12C, Adherent)","Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (SN12C, Adherent)",-0.0
Immunotoxin (HA22) sensitization/mitigation study - treatment arm (High Dose),Immunotoxin (HA22) sensitization/mitigation study - treatment arm (High Dose),-0.0
Immunotoxin (HA22) sensitization/mitigation study - treatment arm (low dose),Immunotoxin (HA22) sensitization/mitigation study - treatment arm (low dose),0.007003018393896176
Immunotoxin (HA22) sensitization/mitigation study. Vehicle arm (PBS),Immunotoxin (HA22) sensitization/mitigation study. Vehicle arm (PBS),0.005093449122550492
Immunotoxin (SS1P) sensitization/mitigation study - treatment arm,Immunotoxin (SS1P) sensitization/mitigation study - treatment arm,0.006590905204111709
Immunotoxin (SS1P) sensitization/mitigation study. Vehicle arm (DMEM),Immunotoxin (SS1P) sensitization/mitigation study. Vehicle arm (DMEM),0.004418667599204958
NCI In Vivo Anticancer Drug Screen. Data for tumor model  ADJ-PC-6 (intraperitoneal) in BALB/cJ mice,NCI In Vivo Anticancer Drug Screen. Data for tumor model  ADJ-PC-6 (intraperitoneal) in BALB/cJ mice,0.013971918879360478
NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice,0.011418286437735512
NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in CD2F1 (CDF1) mice,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in CD2F1 (CDF1) mice,0.010618650449203453
NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (subcutaneous) in B6D2F1 (BDF1) mice,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (subcutaneous) in B6D2F1 (BDF1) mice,-0.0
TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells,TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells,0.0
qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway.,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway.,-0.0
qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen,qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen,0.01500236668117451
A Cell Based Secondary Assay To Explore Cytotoxicity of Compounds that Inhibit Mycobacterium Tuberculosis,A Cell Based Secondary Assay To Explore Cytotoxicity of Compounds that Inhibit Mycobacterium Tuberculosis,-0.0
A High Throughput Confirmatory Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in the absence of Glycerol,A High Throughput Confirmatory Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in the absence of Glycerol,0.01216171683682569
Absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of AddAB recombination protein complex,Absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of AddAB recombination protein complex,-0.0
Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,0.0068105363514096556
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay,Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay,0.0
Colo320 viability from Cell TiterGlo-IC50,Colo320 viability from Cell TiterGlo-IC50,0.031913486979739177
Confirmatory qHTS for gynecologic anti-cancer compounds from libraries of approved drugs and bioactive compounds,Confirmatory qHTS for gynecologic anti-cancer compounds from libraries of approved drugs and bioactive compounds,0.014998542976557085
Counterscreen for AddAB inhibitors: absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of bacterial viability,Counterscreen for AddAB inhibitors: absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of bacterial viability,-0.0
Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,-0.0
Counterscreen for RECBCD inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of AddAB recombination protein complex,Counterscreen for RECBCD inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of AddAB recombination protein complex,0.00664285207153149
Counterscreen for inhibitors of RecBCD: Absorbance-based cell-based high throughput assay to identify inhibitors of bacterial viability,Counterscreen for inhibitors of RecBCD: Absorbance-based cell-based high throughput assay to identify inhibitors of bacterial viability,-0.0
DLD viability from Cell TiterGlo-IC50,DLD viability from Cell TiterGlo-IC50,-0.0
GSK3B-pretreated HCT116 viability from Cell TiterGlo-IC50,GSK3B-pretreated HCT116 viability from Cell TiterGlo-IC50,0.013568745482202667
HCT116 viability from Cell TiterGlo-IC50,HCT116 viability from Cell TiterGlo-IC50,0.011887066446199331
HT-29 viability from Cell TiterGlo-IC50,HT-29 viability from Cell TiterGlo-IC50,0.0056049865625174234
High Throughput Screening of small molecules that kill Mycobacterium tuberculosis,High Throughput Screening of small molecules that kill Mycobacterium tuberculosis,0.02656677047252943
Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate at 0.04 to 200 uM after 40 mins by NMR spectrometric analysis,Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate at 0.04 to 200 uM after 40 mins by NMR spectrometric analysis,0.0
RKO viability from Cell TiterGlo-IC50,RKO viability from Cell TiterGlo-IC50,0.01956633456481802
Rucaparib conditional oncology-focused drug screen on ovarian cancer cells.,Rucaparib conditional oncology-focused drug screen on ovarian cancer cells.,-0.0
SNU-C1 viability from Cell TiterGlo-IC50,SNU-C1 viability from Cell TiterGlo-IC50,-0.0
SW480 viability from Cell TiterGlo-IC50,SW480 viability from Cell TiterGlo-IC50,0.00553258660097015
VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-IC50,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-IC50,0.035710713071165114
Binding affinity towards human CHRM5 in an in vitro assay with cellular components measured by membrane filtration,Binding affinity towards human CHRM5 in an in vitro assay with cellular components measured by membrane filtration,0.0
Binding affinity towards human DRD4 in an in vitro assay with cellular components measured by membrane filtration,Binding affinity towards human DRD4 in an in vitro assay with cellular components measured by membrane filtration,0.0
Binding affinity towards human TACR1 in an in vitro assay with cellular components measured by membrane filtration,Binding affinity towards human TACR1 in an in vitro assay with cellular components measured by membrane filtration,0.0
Compound was evaluated for inhibition of human SCN5A in an in vitro cell-based assay measured by IonWorks automated patch clamp,Compound was evaluated for inhibition of human SCN5A in an in vitro cell-based assay measured by IonWorks automated patch clamp,0.0
Human H1 receptor (Histamine receptors),Human H1 receptor (Histamine receptors),0.0
Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,0.0
Inhibition of human Potassium channel HERG expressed in mammalian cells,Inhibition of human Potassium channel HERG expressed in mammalian cells,0.0
Inhibitory concentration against potassium channel HERG,Inhibitory concentration against potassium channel HERG,0.0
Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells,Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells,0.0
Human D1 receptor (Dopamine receptors),Human D1 receptor (Dopamine receptors),0.0
Human D2 receptor (Dopamine receptors),Human D2 receptor (Dopamine receptors),0.0
Human D3 receptor (Dopamine receptors),Human D3 receptor (Dopamine receptors),0.0
Human D4 receptor (Dopamine receptors),Human D4 receptor (Dopamine receptors),0.0
Human D5 receptor (Dopamine receptors),Human D5 receptor (Dopamine receptors),0.0
Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay,Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay,0.0
Compound was evaluated for inhibition of rat Slc18a2 in an ex vivo assay measured by radioactivity method,Compound was evaluated for inhibition of rat Slc18a2 in an ex vivo assay measured by radioactivity method,0.0
Confirmatory qHTS for activators (rescue) of SARS-CoV-2 Cytopathic Effect (CPE),Confirmatory qHTS for activators (rescue) of SARS-CoV-2 Cytopathic Effect (CPE),-0.0
Human 5-HT2B receptor (5-Hydroxytryptamine receptors),Human 5-HT2B receptor (5-Hydroxytryptamine receptors),0.0
Human SERT (Monoamine transporter subfamily),Human SERT (Monoamine transporter subfamily),0.0
Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,0.0
Mouse Kir3.2 (Inwardly rectifying potassium channels),Mouse Kir3.2 (Inwardly rectifying potassium channels),0.0
Rat 5-HT2A receptor (5-Hydroxytryptamine receptors),Rat 5-HT2A receptor (5-Hydroxytryptamine receptors),0.0
Rat 5-HT6 receptor (5-Hydroxytryptamine receptors),Rat 5-HT6 receptor (5-Hydroxytryptamine receptors),0.0
DSSTox (EPAFHM) EPA Fathead Minnow Acute Toxicity,DSSTox (EPAFHM) EPA Fathead Minnow Acute Toxicity,0.0032193585376446734
Human COX  (Cyclooxygenase),Human COX  (Cyclooxygenase),0.0
Human COX-2  (Cyclooxygenase),Human COX-2  (Cyclooxygenase),0.0
Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay,Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay,0.0
Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay,Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay,0.0
Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,0.0
Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,0.0
Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,0.0
Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,0.0
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,0.0
Ligands of peptide (Class A) GPCRs,Ligands of peptide (Class A) GPCRs,0.0
Solubility by shake flask method,Solubility by shake flask method,0.0
Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,0.0
NCATS Kinetic Aqueous Solubility Profiling,NCATS Kinetic Aqueous Solubility Profiling,0.00470895528992047
NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling,NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling,-0.0
NCATS Rat Liver Microsome Stability Profiling,NCATS Rat Liver Microsome Stability Profiling,0.004672821747839699
Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days,0.0
Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay,Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay,0.0
Antibacterial activity against uropathogenic Escherichia coli UTI89 assessed as degradation of preexisting biofilm after 24 hrs by microscopy,Antibacterial activity against uropathogenic Escherichia coli UTI89 assessed as degradation of preexisting biofilm after 24 hrs by microscopy,0.0
Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay,Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay,0.0
Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay,Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay,0.0
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay,Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay,0.0
Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay,Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay,0.0
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,0.0
Cmax in human,Cmax in human,0.0
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,0.0
NCI Yeast Anticancer Drug Screen. Data for the rad18 strain,NCI Yeast Anticancer Drug Screen. Data for the rad18 strain,-0.0
SANGER: Inhibition of human 22RV1 cell growth in a cell viability assay.,SANGER: Inhibition of human 22RV1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human 5637 cell growth in a cell viability assay.,SANGER: Inhibition of human 5637 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human 639-V cell growth in a cell viability assay.,SANGER: Inhibition of human 639-V cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human 647-V cell growth in a cell viability assay.,SANGER: Inhibition of human 647-V cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human 769-P cell growth in a cell viability assay.,SANGER: Inhibition of human 769-P cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human 786-0 cell growth in a cell viability assay.,SANGER: Inhibition of human 786-0 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human 8305C cell growth in a cell viability assay.,SANGER: Inhibition of human 8305C cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human 8505C cell growth in a cell viability assay.,SANGER: Inhibition of human 8505C cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human A172 cell growth in a cell viability assay.,SANGER: Inhibition of human A172 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human A204 cell growth in a cell viability assay.,SANGER: Inhibition of human A204 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human A2058 cell growth in a cell viability assay.,SANGER: Inhibition of human A2058 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human A2780 cell growth in a cell viability assay.,SANGER: Inhibition of human A2780 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human A427 cell growth in a cell viability assay.,SANGER: Inhibition of human A427 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human A431 cell growth in a cell viability assay.,SANGER: Inhibition of human A431 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human A673 cell growth in a cell viability assay.,SANGER: Inhibition of human A673 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human A704 cell growth in a cell viability assay.,SANGER: Inhibition of human A704 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ABC cell growth in a cell viability assay.,SANGER: Inhibition of human ABC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ACHN cell growth in a cell viability assay.,SANGER: Inhibition of human ACHN cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human AN3-CA cell growth in a cell viability assay.,SANGER: Inhibition of human AN3-CA cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human AU565 cell growth in a cell viability assay.,SANGER: Inhibition of human AU565 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BCPAP cell growth in a cell viability assay.,SANGER: Inhibition of human BCPAP cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BFTC-905 cell growth in a cell viability assay.,SANGER: Inhibition of human BFTC-905 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BFTC-909 cell growth in a cell viability assay.,SANGER: Inhibition of human BFTC-909 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BHY cell growth in a cell viability assay.,SANGER: Inhibition of human BHY cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BPH cell growth in a cell viability assay.,SANGER: Inhibition of human BPH cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human BT-20 cell growth in a cell viability assay.,SANGER: Inhibition of human BT-20 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human C3A cell growth in a cell viability assay.,SANGER: Inhibition of human C3A cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CAKI cell growth in a cell viability assay.,SANGER: Inhibition of human CAKI cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CAL2T cell growth in a cell viability assay.,SANGER: Inhibition of human CAL2T cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CAL-27 cell growth in a cell viability assay.,SANGER: Inhibition of human CAL-27 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CAL-33 cell growth in a cell viability assay.,SANGER: Inhibition of human CAL-33 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CAL-51 cell growth in a cell viability assay.,SANGER: Inhibition of human CAL-51 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CAL-54 cell growth in a cell viability assay.,SANGER: Inhibition of human CAL-54 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CAL-62 cell growth in a cell viability assay.,SANGER: Inhibition of human CAL-62 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CAPAN cell growth in a cell viability assay.,SANGER: Inhibition of human CAPAN cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CHL cell growth in a cell viability assay.,SANGER: Inhibition of human CHL cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human CHP-212 cell growth in a cell viability assay.,SANGER: Inhibition of human CHP-212 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human COR-L105 cell growth in a cell viability assay.,SANGER: Inhibition of human COR-L105 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human COR-L23 cell growth in a cell viability assay.,SANGER: Inhibition of human COR-L23 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human Ca-Ski cell growth in a cell viability assay.,SANGER: Inhibition of human Ca-Ski cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human Ca9-22 cell growth in a cell viability assay.,SANGER: Inhibition of human Ca9-22 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human Calu-3 cell growth in a cell viability assay.,SANGER: Inhibition of human Calu-3 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ChaGo-K cell growth in a cell viability assay.,SANGER: Inhibition of human ChaGo-K cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human DBTRG-05MG cell growth in a cell viability assay.,SANGER: Inhibition of human DBTRG-05MG cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human DMS-273 cell growth in a cell viability assay.,SANGER: Inhibition of human DMS-273 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human DU45 cell growth in a cell viability assay.,SANGER: Inhibition of human DU45 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human Daoy cell growth in a cell viability assay.,SANGER: Inhibition of human Daoy cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human Detroit562 cell growth in a cell viability assay.,SANGER: Inhibition of human Detroit562 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human DoTc2-4510 cell growth in a cell viability assay.,SANGER: Inhibition of human DoTc2-4510 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human EFM9 cell growth in a cell viability assay.,SANGER: Inhibition of human EFM9 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human EFO-27 cell growth in a cell viability assay.,SANGER: Inhibition of human EFO-27 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human EGI cell growth in a cell viability assay.,SANGER: Inhibition of human EGI cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ESS cell growth in a cell viability assay.,SANGER: Inhibition of human ESS cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human FADU cell growth in a cell viability assay.,SANGER: Inhibition of human FADU cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human FTC33 cell growth in a cell viability assay.,SANGER: Inhibition of human FTC33 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human G-401 cell growth in a cell viability assay.,SANGER: Inhibition of human G-401 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human G-402 cell growth in a cell viability assay.,SANGER: Inhibition of human G-402 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human GAMG cell growth in a cell viability assay.,SANGER: Inhibition of human GAMG cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human GCT cell growth in a cell viability assay.,SANGER: Inhibition of human GCT cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human GP5d cell growth in a cell viability assay.,SANGER: Inhibition of human GP5d cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human H4 cell growth in a cell viability assay.,SANGER: Inhibition of human H4 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HCC1569 cell growth in a cell viability assay.,SANGER: Inhibition of human HCC1569 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HCC1806 cell growth in a cell viability assay.,SANGER: Inhibition of human HCC1806 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HCE-4 cell growth in a cell viability assay.,SANGER: Inhibition of human HCE-4 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HCT16 cell growth in a cell viability assay.,SANGER: Inhibition of human HCT16 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HEC cell growth in a cell viability assay.,SANGER: Inhibition of human HEC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HGC-27 cell growth in a cell viability assay.,SANGER: Inhibition of human HGC-27 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HLE cell growth in a cell viability assay.,SANGER: Inhibition of human HLE cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HMV-II cell growth in a cell viability assay.,SANGER: Inhibition of human HMV-II cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HN cell growth in a cell viability assay.,SANGER: Inhibition of human HN cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HO-N cell growth in a cell viability assay.,SANGER: Inhibition of human HO-N cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HOS cell growth in a cell viability assay.,SANGER: Inhibition of human HOS cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HPAF-II cell growth in a cell viability assay.,SANGER: Inhibition of human HPAF-II cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HSC-2 cell growth in a cell viability assay.,SANGER: Inhibition of human HSC-2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HSC-3 cell growth in a cell viability assay.,SANGER: Inhibition of human HSC-3 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HSC-4 cell growth in a cell viability assay.,SANGER: Inhibition of human HSC-4 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HT376 cell growth in a cell viability assay.,SANGER: Inhibition of human HT376 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HT-3 cell growth in a cell viability assay.,SANGER: Inhibition of human HT-3 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HTC-C3 cell growth in a cell viability assay.,SANGER: Inhibition of human HTC-C3 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HuH-7 cell growth in a cell viability assay.,SANGER: Inhibition of human HuH-7 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HuO-3N1 cell growth in a cell viability assay.,SANGER: Inhibition of human HuO-3N1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human HuP-T4 cell growth in a cell viability assay.,SANGER: Inhibition of human HuP-T4 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human IA-LM cell growth in a cell viability assay.,SANGER: Inhibition of human IA-LM cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human J82 cell growth in a cell viability assay.,SANGER: Inhibition of human J82 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human JEG-3 cell growth in a cell viability assay.,SANGER: Inhibition of human JEG-3 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KLE cell growth in a cell viability assay.,SANGER: Inhibition of human KLE cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KOSC-2 cell growth in a cell viability assay.,SANGER: Inhibition of human KOSC-2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KP-4 cell growth in a cell viability assay.,SANGER: Inhibition of human KP-4 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KYSE40 cell growth in a cell viability assay.,SANGER: Inhibition of human KYSE40 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KYSE80 cell growth in a cell viability assay.,SANGER: Inhibition of human KYSE80 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KYSE-270 cell growth in a cell viability assay.,SANGER: Inhibition of human KYSE-270 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KYSE-450 cell growth in a cell viability assay.,SANGER: Inhibition of human KYSE-450 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KYSE-510 cell growth in a cell viability assay.,SANGER: Inhibition of human KYSE-510 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human KYSE-70 cell growth in a cell viability assay.,SANGER: Inhibition of human KYSE-70 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LCLC03H cell growth in a cell viability assay.,SANGER: Inhibition of human LCLC03H cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LCLC-97TM1 cell growth in a cell viability assay.,SANGER: Inhibition of human LCLC-97TM1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LK-2 cell growth in a cell viability assay.,SANGER: Inhibition of human LK-2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LU-99A cell growth in a cell viability assay.,SANGER: Inhibition of human LU-99A cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human LoVo cell growth in a cell viability assay.,SANGER: Inhibition of human LoVo cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human M14 cell growth in a cell viability assay.,SANGER: Inhibition of human M14 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MC-IXC cell growth in a cell viability assay.,SANGER: Inhibition of human MC-IXC cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MDA-MB-415 cell growth in a cell viability assay.,SANGER: Inhibition of human MDA-MB-415 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human ME80 cell growth in a cell viability assay.,SANGER: Inhibition of human ME80 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MEL-HO cell growth in a cell viability assay.,SANGER: Inhibition of human MEL-HO cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MEL-JUSO cell growth in a cell viability assay.,SANGER: Inhibition of human MEL-JUSO cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MG-63 cell growth in a cell viability assay.,SANGER: Inhibition of human MG-63 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MHH-ES cell growth in a cell viability assay.,SANGER: Inhibition of human MHH-ES cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay.,SANGER: Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MKN1 cell growth in a cell viability assay.,SANGER: Inhibition of human MKN1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MKN28 cell growth in a cell viability assay.,SANGER: Inhibition of human MKN28 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human MKN45 cell growth in a cell viability assay.,SANGER: Inhibition of human MKN45 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human Mewo cell growth in a cell viability assay.,SANGER: Inhibition of human Mewo cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H1437 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H1437 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H1563 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H1563 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H1703 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H1703 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H1792 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H1792 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H2030 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H2030 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H2087 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H2087 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H2122 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H2122 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H2170 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H2170 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H2228 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H2228 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H28 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H28 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H292 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H292 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H358 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H358 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H650 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H650 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H661 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H661 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-H810 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-H810 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NCI-N87 cell growth in a cell viability assay.,SANGER: Inhibition of human NCI-N87 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NUGC-3 cell growth in a cell viability assay.,SANGER: Inhibition of human NUGC-3 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human NY cell growth in a cell viability assay.,SANGER: Inhibition of human NY cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human OAW-28 cell growth in a cell viability assay.,SANGER: Inhibition of human OAW-28 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human OAW-42 cell growth in a cell viability assay.,SANGER: Inhibition of human OAW-42 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human OE33 cell growth in a cell viability assay.,SANGER: Inhibition of human OE33 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human OVCAR-8 cell growth in a cell viability assay.,SANGER: Inhibition of human OVCAR-8 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay.,SANGER: Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human PA cell growth in a cell viability assay.,SANGER: Inhibition of human PA cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human PANC-03-27 cell growth in a cell viability assay.,SANGER: Inhibition of human PANC-03-27 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human PANC0-05 cell growth in a cell viability assay.,SANGER: Inhibition of human PANC0-05 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human PC4 cell growth in a cell viability assay.,SANGER: Inhibition of human PC4 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human PC-3 cell growth in a cell viability assay.,SANGER: Inhibition of human PC-3 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human PFSK cell growth in a cell viability assay.,SANGER: Inhibition of human PFSK cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RCM cell growth in a cell viability assay.,SANGER: Inhibition of human RCM cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RD cell growth in a cell viability assay.,SANGER: Inhibition of human RD cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RERF-LC-MS cell growth in a cell viability assay.,SANGER: Inhibition of human RERF-LC-MS cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RPMI-2650 cell growth in a cell viability assay.,SANGER: Inhibition of human RPMI-2650 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RPMI-7951 cell growth in a cell viability assay.,SANGER: Inhibition of human RPMI-7951 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human RT12 cell growth in a cell viability assay.,SANGER: Inhibition of human RT12 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human S17 cell growth in a cell viability assay.,SANGER: Inhibition of human S17 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SAS cell growth in a cell viability assay.,SANGER: Inhibition of human SAS cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SCC5 cell growth in a cell viability assay.,SANGER: Inhibition of human SCC5 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SCC-25 cell growth in a cell viability assay.,SANGER: Inhibition of human SCC-25 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SCC-4 cell growth in a cell viability assay.,SANGER: Inhibition of human SCC-4 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SF295 cell growth in a cell viability assay.,SANGER: Inhibition of human SF295 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SK-HEP cell growth in a cell viability assay.,SANGER: Inhibition of human SK-HEP cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SK-LU cell growth in a cell viability assay.,SANGER: Inhibition of human SK-LU cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SK-MES cell growth in a cell viability assay.,SANGER: Inhibition of human SK-MES cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SKG-IIIa cell growth in a cell viability assay.,SANGER: Inhibition of human SKG-IIIa cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SN12C cell growth in a cell viability assay.,SANGER: Inhibition of human SN12C cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SNU-423 cell growth in a cell viability assay.,SANGER: Inhibition of human SNU-423 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SNU-449 cell growth in a cell viability assay.,SANGER: Inhibition of human SNU-449 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SNU-C2B cell growth in a cell viability assay.,SANGER: Inhibition of human SNU-C2B cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SW1088 cell growth in a cell viability assay.,SANGER: Inhibition of human SW1088 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SW13 cell growth in a cell viability assay.,SANGER: Inhibition of human SW13 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SW1573 cell growth in a cell viability assay.,SANGER: Inhibition of human SW1573 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SW1710 cell growth in a cell viability assay.,SANGER: Inhibition of human SW1710 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SW48 cell growth in a cell viability assay.,SANGER: Inhibition of human SW48 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SW620 cell growth in a cell viability assay.,SANGER: Inhibition of human SW620 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SW756 cell growth in a cell viability assay.,SANGER: Inhibition of human SW756 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human SW982 cell growth in a cell viability assay.,SANGER: Inhibition of human SW982 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human T98G cell growth in a cell viability assay.,SANGER: Inhibition of human T98G cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human TCCSUP cell growth in a cell viability assay.,SANGER: Inhibition of human TCCSUP cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human TE1 cell growth in a cell viability assay.,SANGER: Inhibition of human TE1 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human TGBC24TKB cell growth in a cell viability assay.,SANGER: Inhibition of human TGBC24TKB cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human TYK-nu cell growth in a cell viability assay.,SANGER: Inhibition of human TYK-nu cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human UM-UC-3 cell growth in a cell viability assay.,SANGER: Inhibition of human UM-UC-3 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human VM-CUB cell growth in a cell viability assay.,SANGER: Inhibition of human VM-CUB cell growth in a cell viability assay.,0.0
Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,0.009593742384206032
Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Full-Length Luciferase Counterscreen assay,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Full-Length Luciferase Counterscreen assay,0.0032106090871649204
Compound was evaluated for inhibition of human CACNA1C in an in vitro cell-based assay measured by IonWorks automated patch clamp,Compound was evaluated for inhibition of human CACNA1C in an in vitro cell-based assay measured by IonWorks automated patch clamp,0.0
Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range),Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range),0.0
"Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta subunits","Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta subunits",0.0
Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes,Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes,0.0
Inhibition of hERG K channel,Inhibition of hERG K channel,0.0
Antiviral activity against HIV1,Antiviral activity against HIV1,0.0
Cytotoxicity against human HeLa cells,Cytotoxicity against human HeLa cells,0.0
Confirmatory qHTS for inhibitors of MERS-S pseudo-typed particle cell entry,Confirmatory qHTS for inhibitors of MERS-S pseudo-typed particle cell entry,0.004900022831913239
Confirmatory qHTS for inhibitors of SARS-S pseudo-typed particle cell entry,Confirmatory qHTS for inhibitors of SARS-S pseudo-typed particle cell entry,-0.0
VSV-G qHTS counterscreen for inhibitors of MERS-S pseudo-typed particle cell entry,VSV-G qHTS counterscreen for inhibitors of MERS-S pseudo-typed particle cell entry,0.009415289175828543
VSV-G qHTS counterscreen for inhibitors of SARS-S pseudo-typed particle cell entry,VSV-G qHTS counterscreen for inhibitors of SARS-S pseudo-typed particle cell entry,-0.0
Antimicrobial activity against Carnobacterium divergens BM4490 expressing beta-lactamase CAD1 at 0.5 McFarland inoculum size by E-test,Antimicrobial activity against Carnobacterium divergens BM4490 expressing beta-lactamase CAD1 at 0.5 McFarland inoculum size by E-test,0.0
Antimicrobial activity against Carnobacterium divergens BM4490 expressing beta-lactamase CAD1 at 3 McFarland inoculum size by E-test,Antimicrobial activity against Carnobacterium divergens BM4490 expressing beta-lactamase CAD1 at 3 McFarland inoculum size by E-test,0.0
Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid,Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid,0.0
Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid,Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid,0.0
Human 5-HT6 receptor (5-Hydroxytryptamine receptors),Human 5-HT6 receptor (5-Hydroxytryptamine receptors),0.0
Human M1 receptor (Acetylcholine receptors (muscarinic)),Human M1 receptor (Acetylcholine receptors (muscarinic)),0.0
Human M2 receptor (Acetylcholine receptors (muscarinic)),Human M2 receptor (Acetylcholine receptors (muscarinic)),0.0
Human M3 receptor (Acetylcholine receptors (muscarinic)),Human M3 receptor (Acetylcholine receptors (muscarinic)),0.0
Human M4 receptor (Acetylcholine receptors (muscarinic)),Human M4 receptor (Acetylcholine receptors (muscarinic)),0.0
Human NET (Monoamine transporter subfamily),Human NET (Monoamine transporter subfamily),0.0
Inhibition of human ERG in MCF7 cells,Inhibition of human ERG in MCF7 cells,0.0
Inhibition of human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel) in open state,Inhibition of human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel) in open state,0.0
K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,0.0
Rat 5-HT7 receptor (5-Hydroxytryptamine receptors),Rat 5-HT7 receptor (5-Hydroxytryptamine receptors),0.0
Human DAT (Monoamine transporter subfamily),Human DAT (Monoamine transporter subfamily),0.0
SANGER: Inhibition of human 23132-87 cell growth in a cell viability assay.,SANGER: Inhibition of human 23132-87 cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human AGS cell growth in a cell viability assay.,SANGER: Inhibition of human AGS cell growth in a cell viability assay.,0.0
SANGER: Inhibition of human IGROV cell growth in a cell viability assay.,SANGER: Inhibition of human IGROV cell growth in a cell viability assay.,0.0
Antimicrobial activity against Pseudomonas aeruginosa 2A3 tracheal isolates from mechanically ventilated tuberculosis patient,Antimicrobial activity against Pseudomonas aeruginosa 2A3 tracheal isolates from mechanically ventilated tuberculosis patient,-0.0
Antimicrobial activity against Pseudomonas aeruginosa 2A5 tracheal isolates from mechanically ventilated tuberculosis patient,Antimicrobial activity against Pseudomonas aeruginosa 2A5 tracheal isolates from mechanically ventilated tuberculosis patient,0.0
Antimicrobial activity against Pseudomonas aeruginosa 3B1 tracheal isolates from mechanically ventilated tuberculosis patient,Antimicrobial activity against Pseudomonas aeruginosa 3B1 tracheal isolates from mechanically ventilated tuberculosis patient,-0.0
Antimicrobial activity against Pseudomonas aeruginosa IA5 tracheal isolates from mechanically ventilated tuberculosis patient,Antimicrobial activity against Pseudomonas aeruginosa IA5 tracheal isolates from mechanically ventilated tuberculosis patient,-0.0
Antimicrobial activity against Pseudomonas aeruginosa P21.21 tracheal isolates from mechanically ventilated tuberculosis patient,Antimicrobial activity against Pseudomonas aeruginosa P21.21 tracheal isolates from mechanically ventilated tuberculosis patient,0.0
Antimicrobial activity against Pseudomonas aeruginosa P21.23 tracheal isolates from mechanically ventilated tuberculosis patient,Antimicrobial activity against Pseudomonas aeruginosa P21.23 tracheal isolates from mechanically ventilated tuberculosis patient,0.0
Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A,0.0
Human 5-HT1A receptor (5-Hydroxytryptamine receptors),Human 5-HT1A receptor (5-Hydroxytryptamine receptors),0.0
Human 5-HT2A receptor (5-Hydroxytryptamine receptors),Human 5-HT2A receptor (5-Hydroxytryptamine receptors),0.0
Human 5-HT2C receptor (5-Hydroxytryptamine receptors),Human 5-HT2C receptor (5-Hydroxytryptamine receptors),0.0
Human 5-HT7 receptor (5-Hydroxytryptamine receptors),Human 5-HT7 receptor (5-Hydroxytryptamine receptors),0.0
Human alpha2A-adrenoceptor (Adrenoceptors),Human alpha2A-adrenoceptor (Adrenoceptors),0.0
Human alpha2B-adrenoceptor (Adrenoceptors),Human alpha2B-adrenoceptor (Adrenoceptors),0.0
Human alpha2C-adrenoceptor (Adrenoceptors),Human alpha2C-adrenoceptor (Adrenoceptors),0.0
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,0.0
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay,Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay,0.0
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay,Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay,0.0
Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC,Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC,0.0
"Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay","Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",0.0
"Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay","Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",0.0
Inhibition of human cytochrome P450 3A4,Inhibition of human cytochrome P450 3A4,0.0
TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells,TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells,0.0
TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells,TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells,0.0
"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, ratio channel","qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, ratio channel",0.0124457173979975
qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation,qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation,0.01520838495568082
Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay,Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay,0.0
Inhibition of DR24 in Dhcr7-deficient mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis,Inhibition of DR24 in Dhcr7-deficient mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis,0.0
Confirmatory qHTS for antagonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2),Confirmatory qHTS for antagonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2),0.023704691959517424
Inhibition of cigarette smoke extract (CSE) and LPS-stimulated mouse B cell migration at 1 uM relative to control,Inhibition of cigarette smoke extract (CSE) and LPS-stimulated mouse B cell migration at 1 uM relative to control,0.0
Inhibition of human BSEP expressed in HEK293 cell membrane vesicles assessed as reduction in 3H-TCA uptake incubated for 5 mins by radiodetection method,Inhibition of human BSEP expressed in HEK293 cell membrane vesicles assessed as reduction in 3H-TCA uptake incubated for 5 mins by radiodetection method,0.0
"3H-CGP 12177 Whole Cell Binding Assay from Article 10.1038/sj.bjp.0706048: ""The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.""","3H-CGP 12177 Whole Cell Binding Assay from Article 10.1038/sj.bjp.0706048: ""The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.""",0.0
Human alpha1D-adrenoceptor (Adrenoceptors),Human alpha1D-adrenoceptor (Adrenoceptors),0.0
Human beta1-adrenoceptor (Adrenoceptors),Human beta1-adrenoceptor (Adrenoceptors),0.0
Human beta2-adrenoceptor (Adrenoceptors),Human beta2-adrenoceptor (Adrenoceptors),0.0
Confirmation assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytes,Confirmation assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytes,-0.0
Confirmation qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmation qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),0.008233299026707178
TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells,TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells,0.0
A Counter Screen to identiry small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,A Counter Screen to identiry small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,-0.0
A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhimurium identified in the primary screen,A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhimurium identified in the primary screen,-0.0
A screen for inhibitors of the PhoP regulon in Salmonella Typhimurium using a modified counterscreen.,A screen for inhibitors of the PhoP regulon in Salmonella Typhimurium using a modified counterscreen.,-0.0
Inhibition of GST-tagged astrosclera willeyana Astrosclerin-3 expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay,Inhibition of GST-tagged astrosclera willeyana Astrosclerin-3 expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay,0.0
Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia carbonic anhydrase-2 assessed as CO2 hydrase activity by stopped-flow assay,Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia carbonic anhydrase-2 assessed as CO2 hydrase activity by stopped-flow assay,0.0
Inhibition of Nostoc commune gamma carbonic anhydrase by CO2 hydration assay,Inhibition of Nostoc commune gamma carbonic anhydrase by CO2 hydration assay,0.0
Inhibition of Nostoc commune gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay,Inhibition of Nostoc commune gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay,0.0
Inhibition of Plasmodium falciparum Eta-carbonic anhydrase pre-incubated for 15 mins before CO2 substrate addition by stopped-flow CO2 hydration assay,Inhibition of Plasmodium falciparum Eta-carbonic anhydrase pre-incubated for 15 mins before CO2 substrate addition by stopped-flow CO2 hydration assay,0.0
Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 1 at pH 8.3 by stopped flow CO2 hydration assay,Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 1 at pH 8.3 by stopped flow CO2 hydration assay,0.0
Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 2 at pH 8.3 by stopped flow CO2 hydration assay,Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 2 at pH 8.3 by stopped flow CO2 hydration assay,0.0
Inhibition of Sulfurihydrogenibium yellowstonense YO3AOP1 recombinant carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay,Inhibition of Sulfurihydrogenibium yellowstonense YO3AOP1 recombinant carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay,0.0
Inhibition of Thalassiosira weissflogii delta carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay,Inhibition of Thalassiosira weissflogii delta carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay,0.0
Inhibition of Vibrio cholerae Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis,Inhibition of Vibrio cholerae Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis,0.0
Inhibition of Vibrio cholerae beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay,Inhibition of Vibrio cholerae beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay,0.0
Inhibition of Vibrio cholerae beta-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay,Inhibition of Vibrio cholerae beta-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay,0.0
Inhibition of human Carbonic anhydrase2 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay,Inhibition of human Carbonic anhydrase2 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay,0.0
Inhibition of human carbonic anhydrase 2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis,Inhibition of human carbonic anhydrase 2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis,0.0
Inhibition of human carbonic anhydrase 2 incubated for 15 mins by stopped-flow CO2 hydration assay,Inhibition of human carbonic anhydrase 2 incubated for 15 mins by stopped-flow CO2 hydration assay,0.0
Inhibition of human carbonic anhydrase 2 pre-incubated for 15 mins by stopped-flow CO2 hydration assay,Inhibition of human carbonic anhydrase 2 pre-incubated for 15 mins by stopped-flow CO2 hydration assay,0.0
Inhibition of human carbonic anhydrase 2 preincubated for 15 mins by CO2 hydrase stopped flow assay,Inhibition of human carbonic anhydrase 2 preincubated for 15 mins by CO2 hydrase stopped flow assay,0.0
Inhibition of human carbonic anhydrase-2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay,Inhibition of human carbonic anhydrase-2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay,0.0
Inhibition of human carbonic anhydrase-2 by stopped-flow CO2 hydration assay,Inhibition of human carbonic anhydrase-2 by stopped-flow CO2 hydration assay,0.0
Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stop flow CO2 hydrase assay,Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stop flow CO2 hydrase assay,0.0
Inhibition of human recombinant Carbonic anhydrase 2 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method,Inhibition of human recombinant Carbonic anhydrase 2 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method,0.0
Inhibition of human recombinant carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay,Inhibition of human recombinant carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay,0.0
Inhibition of human recombinant carbonic anhydrase 2 at pH 7.5 by stopped flow CO2 hydration assay,Inhibition of human recombinant carbonic anhydrase 2 at pH 7.5 by stopped flow CO2 hydration assay,0.0
Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay,Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay,0.0
Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay,Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay,0.0
Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydration assay,Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydration assay,0.0
Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by CO2 hydration stopped-flow assay,Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by CO2 hydration stopped-flow assay,0.0
Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay,Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay,0.0
Inhibition of human recombinant carbonic anhydrase-2 by stopped flow CO2 hydrase assay method,Inhibition of human recombinant carbonic anhydrase-2 by stopped flow CO2 hydrase assay method,0.0
Inhibition of recombinant Colwellia psychrerythraea gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay,Inhibition of recombinant Colwellia psychrerythraea gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay,0.0
Inhibition of recombinant Enterobacter sp. B13 beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay,Inhibition of recombinant Enterobacter sp. B13 beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay,0.0
Inhibition of recombinant Nostoc commune gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydrase assay,Inhibition of recombinant Nostoc commune gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydrase assay,0.0
Inhibition of recombinant Sulfurihydrogenibium yellowstonense YO3AOP1 carbonic anhydrase by stopped flow CO2 hydrase assay,Inhibition of recombinant Sulfurihydrogenibium yellowstonense YO3AOP1 carbonic anhydrase by stopped flow CO2 hydrase assay,0.0
Inhibition of recombinant Thiomicrospira crunogena XCL-2 carbonic anhydrase by stopped flow CO2 hydrase assay,Inhibition of recombinant Thiomicrospira crunogena XCL-2 carbonic anhydrase by stopped flow CO2 hydrase assay,0.0
Inhibition of recombinant Vibrio cholerae gamma-carbonic anhydrase preincubated for 15 mins by stopped-flow CO2 hydration assay,Inhibition of recombinant Vibrio cholerae gamma-carbonic anhydrase preincubated for 15 mins by stopped-flow CO2 hydration assay,0.0
Inhibition of recombinant human carbonic anhydrase-2 by stopped flow CO2 hydrase assay,Inhibition of recombinant human carbonic anhydrase-2 by stopped flow CO2 hydrase assay,0.0
Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs,Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs,0.0
Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,0.0
Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A,Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A,0.0
Human 5-HT1B receptor (5-Hydroxytryptamine receptors),Human 5-HT1B receptor (5-Hydroxytryptamine receptors),0.0
Human 5-HT1D receptor (5-Hydroxytryptamine receptors),Human 5-HT1D receptor (5-Hydroxytryptamine receptors),0.0
Human alpha1A-adrenoceptor (Adrenoceptors),Human alpha1A-adrenoceptor (Adrenoceptors),0.0
Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F,Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F,0.0
Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e,Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e,0.0
Human 5-HT1F receptor (5-Hydroxytryptamine receptors),Human 5-HT1F receptor (5-Hydroxytryptamine receptors),0.0
Human 5-ht1e receptor (5-Hydroxytryptamine receptors),Human 5-ht1e receptor (5-Hydroxytryptamine receptors),0.0
Inhibition of human ERG channel,Inhibition of human ERG channel,0.0
Human alpha1B-adrenoceptor (Adrenoceptors),Human alpha1B-adrenoceptor (Adrenoceptors),0.0
Human delta receptor (Opioid receptors),Human delta receptor (Opioid receptors),0.0
Human kappa receptor (Opioid receptors),Human kappa receptor (Opioid receptors),0.0
Inhibition of rapid delayed inward rectifying potassium current (IKr) measured using manual patch clamp assay,Inhibition of rapid delayed inward rectifying potassium current (IKr) measured using manual patch clamp assay,0.0
